Validation and verification of an analytical method to identify and quantify selected amphetamine-related drugs in whole blood by Alamir, Ahmad
1 
 
Validation and Verification of an Analytical Method to Identify and Quantify Selected 
Amphetamine-Related Drugs in Whole Blood 
 
 
 
by 
 
 
Ahmad Alamir 
 
 
 
A thesis submitted in partial fulfillment of the requirements for the degree of 
Master of Science (MSc) in Chemical Sciences 
 
 
 
 
The Faculty of Graduate Studies 
Laurentian University 
Sudbury, Ontario, Canada 
 
 
 
© Ahmad Alamir, 2018 
 
 
  
ii 
THESIS DEFENCE COMMITTEE/COMITÉ DE SOUTENANCE DE THÈSE 
Laurentian Université/Université Laurentienne 
Faculty of Graduate Studies/Faculté des études supérieures 
 
Title of Thesis     
Titre de la thèse   Validation and Verification of an Analytical Method to Identify and 
QuantifySelected Amphetamine-Related Drugs in Whole Blood 
 
Name of Candidate   
Nom du candidat    Alamir, Ahmad 
       
Degree                            
Diplôme                            Master of Science 
 
Department/Program    Date of Defence 
Département/Programme  Chemical Sciences  Date de la soutenance February 5, 2018 
                                                       
APPROVED/APPROUVÉ 
 
Thesis Examiners/Examinateurs de thèse: 
                                                      
Dr. James Watterson  
(Supervisor/Directeur de thèse) 
 
Dr. Thomas Merritt    
(Committee member/Membre du comité)    
        
Dr. Nelson Belzile      
(Committee member/Membre du comité)    
      Approved for the Faculty of Graduate Studies 
      Approuvé pour la Faculté des études supérieures 
      Dr. David Lesbarrères 
      Monsieur David Lesbarrères 
Dr. Vivienne Luk      Dean, Faculty of Graduate Studies 
(External Examiner/Examinateur externe)   Doyen, Faculté des études supérieures 
 
                                                                                                                                  
ACCESSIBILITY CLAUSE AND PERMISSION TO USE 
 
I, Ahmad Alamir, hereby grant to Laurentian University and/or its agents the non-exclusive license to archive and 
make accessible my thesis, dissertation, or project report in whole or in part in all forms of media, now or for the 
duration of my copyright ownership. I retain all other ownership rights to the copyright of the thesis, dissertation or 
project report. I also reserve the right to use in future works (such as articles or books) all or part of this thesis, 
dissertation, or project report. I further agree that permission for copying of this thesis in any manner, in whole or in 
part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their 
absence, by the Head of the Department in which my thesis work was done. It is understood that any copying or 
publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written 
permission. It is also understood that this copy is being made available in this form by the authority of the copyright 
owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted 
by the copyright laws without written authority from the copyright owner. 
 
iii 
 
 
Abstract 
 
The abuse of amphetamine-related drugs (ARDs) is an epidemiological phenomenon in Saudi 
Arabia. This drug abuse is found to play an important role in early mortality due to traffic 
accidents, violence, and overdose. Therefore, control ARDs abuse is crucial. In forensic 
toxicology, ARDs analysis is carried out to identify human actions, such as driving under the 
influence of drugs, clarify the manner and cause of death, and elucidate drug use. This study has 
yielded practical analytical assay to using whole blood (WB) as a biological matrix in ARDs 
analysis by using ultra performance liquid chromatography in coupling with quadrupole time of 
flight mass spectrometry (UPLC-qTOF-MS). Here, two different types of solid phase extraction 
(SPE) were evaluated. Molecularly imprinted polymers (MIP-SPE) was found to deliver a highly 
clean extract, however, ephedrine (EPH) interference was proved to leach from the polymer 
matrix of the sorbent materials. Mixed mode cation exchange (MMSPE) was found ideal to 
extract ARDs from WB matrices. The analytical method was developed and validated according 
to the Scientific Working Group for Forensic Toxicology (SWGTOX) Standard Practices. The 
validated method was found capable of quantitative analysis of methylphenethylamine (BMP) 
and detection of one of its metabolites in WBs of rats exposed to BMP by peritoneal injections.    
Keywords 
Forensic Toxicology, ARDs, WB, UPLC-qTOF-MS, MIP-SPE, EPH, MMSPE, 
SWGTOX, BMP. 
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Chapter 1: 
1. Introduction
1.1 General Introduction to Forensic Toxicology 
Poisons are substances that are harmful to living organisms when absorbed, ingested, or 
inhaled in sufficient quantities; toxicology is the study of all such poisons [1]. Encompassing 
both modern analytical chemistry and fundamental toxicology, forensic toxicology is defined as 
the study of the effects of drugs and poisons on human beings in a medico-legal context [2]. 
Post-mortem toxicology is the application of forensic toxicology in death investigations.  
1.2 Samples Used for Forensic Toxicological Analysis 
Although currently forensic toxicological analyses may be performed using a wide range of 
sample matrices, such as urine, bile, vitreous humor, hair, saliva, sweat, and nails, blood is the 
most commonly used matrix for quantifying drugs and their pharmacologically active 
metabolites, and for correlating the findings with the extent of toxicity [3, 4]. Besides the 
cerebrospinal fluid, blood is the only biological fluid that reflects drug concentrations in the 
brain [3]. Furthermore, the determination of drug concentrations in the blood facilitates the rapid 
approximation of the cut-off values for subsequent confirmatory analyses without yielding too 
many false positives [5]. 
1.3  Physiological and Chemical Properties of Blood 
Understanding the crucial role of blood in forensic toxicological analysis requires extensive 
knowledge about its composition, properties, and functions. Blood is a fluid connective tissue, 
which constantly circulates throughout the body to provide nutrients and oxygen to each cell, and 
to collect waste products from them. It is a complex mixture of solubilized proteins and fats as 
well as suspended cells and their fragments in a clear aqueous fluid known as plasma [6, 7]. The 
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three types of suspended cells are red blood cells (erythrocytes), white blood cells (leukocytes), 
and platelets (thrombocytes). Erythrocytes represent more than 90% of blood cells; they are 
responsible for the relatively high blood viscosity. These blood cells are normally distributed in 
the plasma due to the continuous motion of the blood. However, they immediately precipitate in 
stagnant plasma because of their higher mass densities than that of plasma. Moreover, blood 
centrifugation produces three layers based on the differences in mass densities as shown in 
Figure 1 [8, 9]. Therefore, blood samples contain many endogenous (salts, carbohydrates, 
amines, urea, lipids, peptides, and metabolites) and exogenous components (anticoagulants)  
[10].  
 
 
Figure 1: Composition of blood [8] 
1.4  Analysis of Drugs in Blood 
Blood is primarily responsible for the systemic circulation of a variety of substances, 
including drugs. An orally administered drug reaches the systemic circulation after absorption 
from the gastrointestinal tract; this is a relatively slow process. However, an intravenously 
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administered drug rapidly enters the blood stream directly, not requiring an absorption phase. 
Once in the blood stream, the drug is distributed to all the tissues; tissue uptake of a drug 
depends on the properties of both the drug and the tissue in question [13]. Hence, the 
identification of the physiochemical properties of a drug is required to facilitate its extraction 
from whole blood (WB) samples. Such specimens must undergo a series of sample pretreatment 
and extraction steps to remove any endogenous and exogenous substances that may cause 
analytical interferences; pretreatment is also performed to concentrate drug samples prior to 
injection into a chromatographic column. 
1.5 Pretreatment of Whole Blood Samples and Drug Extraction 
Sample pretreatment and extraction prior to chromatographic analysis are critical for the 
quantification of trace drug concentrations in WB samples [14]. Drugs in WB samples may be 
bound to proteins; therefore, it is necessary to disrupt drug-protein binding and increase the 
fraction of free drugs prior to extraction. Commonly used extraction techniques include filtration 
pass-through extraction (FPTE), liquid-liquid extraction (LLE), solid phase extraction (SPE), 
supported-liquid extraction, online SPE, and hybrid SPE/protein precipitation extraction [15]. 
1.5.1 Protein Precipitation   
WB is rich in hemoglobin and other plasma proteins that may cause significant interference or 
damage in instrumental analysis. Therefore, it is vital to release the drug from protein-bound 
complexes prior to precipitate for accurate analysis. Protein precipitation is carried out in two 
steps: hemolysis and precipitation. 
1.5.1.1  Hemolysis 
 
Hemolysis is a process that releases erythrocyte-bound drugs and metabolites [16–18]. 
Hemolysis is vital for the accurate and reproducible quantification of drugs and their metabolites 
4 
 
in WB samples. Thus, it is important to lyse erythrocytes to account for any drug taken up by 
erythrocytes and extracellular fluid. Osmotic breakdown of erythrocytes is commonly used to 
cause hemolysis. In this process, erythrocytes are lysed by diluting WB with an equal volume of 
water followed by vortex mixing or sonication [17]. Inorganic denaturation is another way to 
perform hemolysis and ease drug extraction from WB samples [17, 18]. In this approach, ZnSO4 
is used as a protein denaturant and added to WB in a ratio of 1:5. The Zn2+ ion forms coordinate 
bonds with the amino acids of erythrocytic membrane proteins to form insoluble metal-protein 
complexes that precipitate and lyse the cells. Additionally, protons are displaced from the 
coordinated amino acids to decrease the pH of the sample. The acidic pH lowers the partition 
coefficient of the drug and enhances its solubility in acetonitrile (ACN), which is used as a 
precipitant in the precipitation step.  
1.5.1.2   Precipitation 
 
Precipitation can be carried out using water miscible organic solvents, acids, or inorganic salts 
followed by the addition of an organic solvent. Water miscible organic solvents, such as ACN 
and methanol (MeOH), precipitate proteins by lowering the dielectric constant of WB, thereby 
exposing the charges on the proteins and increasing protein-protein electrostatic interactions. 
Addition of an organic solvent displaces the arrangement of water molecules around 
hydrophobic regions on protein surfaces, thereby minimizing hydrophobic interactions between 
proteins. Consequently, electrostatic interactions predominate and lead to protein aggregation 
[17, 18]. ACN is a more efficient precipitation agent than MeOH because the triple bond in its 
structure effectively displaces water molecules by forming pi-stacking bonds with cationic and 
aromatic moieties on protein surfaces [17, 19]. Moreover, it is an aprotic solvent that accepts 
protons and forms hydrogen bonds with water molecules. Thus, using an acid as a hemolytic 
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agent prior to precipitation with ACN improves the recovery of analytes [20]. Interestingly, 
MeOH is a protic solvent that can be used along with ACN to increase the recovery of 
hydrophobic analytes by improving their solubility. Following hemolysis by osmotic breakdown, 
a mixture of ACN and MeOH can be added to the sample to precipitate the proteins.  
Proteins may also be precipitated by the addition of acids, such as trichloroacetic acid (TCA), 
HClO4, HCl, and tungstic acid. However, these strong acids can have negative effects on the 
drug that needs to be extracted; pilot testing may be needed in such cases [21]. After hemolyzing 
WB samples by osmotic breakdown, 10 %TCA, 1 % HCl, or 6% HClO4 may be added to the 
sample in a 1:2 ratio [17].  
The use of organic salts, such as ZnSO4, for hemolysis followed by the addition of a water-
miscible organic solvent is also widely used. In this method, the sample is centrifuged after 5% 
ZnSO4 is added to the WB sample in a 1:5 ratio, and the resultant pellet is discarded. Further, a 
water miscible organic solvent, such as ACN, MeOH, or their mixture, is added to the recovered 
portion of the sample in a 2:1 ratio. Finally, the mixture is centrifuged, and the supernatant is 
recovered [17].  
1.5.2       Analyte Extraction from Pretreated Whole Blood Samples 
After denaturing and precipitating the proteins in WB samples, the analytes of interest may be 
extracted using three different techniques, including FPTE, LLE, and SPE. 
1.5.2.1      Filtration Pass Through Extraction 
FPTE is a hybrid precipitation/SPE technique that has been increasingly used over the past 
few years as a method for the selective removal of phospholipids and precipitated proteins [22–
26]. This extraction technology incorporates a simple protein precipitation step with a fast and 
robust SPE method that is designed to remove phospholipids. Each of the distinct types of 
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commercially available plates, such as Ostro™ (Waters) and Hybrid SPE™ (Sigma Aldrich), 
relies on different principles of extraction. The Ostro™ plate uses a C18 stationary phase for 
retaining phospholipids and precipitated proteins [22]. This plate displays high affinity towards 
phospholipids, and low affinity towards a wide range of basic, neutral, and acidic compounds 
[27]. This plate has been reported to effectively remove phospholipids and precipitated proteins 
from WB, serum, and plasma samples [28–30]. Moreover, the Hybrid SPE is designed to retain 
phospholipids based on Lewis acid-base interactions that occur between zirconia ions bonded to 
the stationary phase and the phosphate group of phospholipids. Compared to conventional 
protein precipitation techniques, FPTE has been found to significantly lower phospholipid 
content in the samples [23]. 
1.5.2.2 Liquid-Liquid Extraction  
LLE is a separation technique in which the analytes of interest are transferred from one phase 
to another when immiscible or partially miscible liquids are in contact with each other [31]. By 
adding organic and aqueous solvents with appropriate pH control, the analytes of interest can be 
extracted from the WB matrix. This method of extraction relies on the pH of the added solvent 
mixture. Hence, at acidic pH, organic acids are more soluble in organic solvents than in aqueous 
solvents. Thus, acidic analytes must be ionized to facilitate their extraction. Hence, to extract 
them from an organic solvent to an aqueous solvent, acidic analytes must be ionized by shifting 
the pH range to alkaline. Similarly, organic bases are more soluble in organic solvents than in 
aqueous solvents at alkaline pH. Thus, they may be extracted by changing the pH to the acidic 
range. Typically, the pH of the solvent mixture must be between the pKa of the analytes of 
interest and pKa + 2 (for acidic analytes) or pKa – 2 (for basic analytes) [16, 22, 32]. The 
advantages and disadvantages of LLE are listed in Table 1 (page 9). 
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1.5.2.3     Solid Phase Extraction 
   SPE is a separation technique in which the analytes of interest are selectively transferred 
from a liquid phase to a solid sorbent. Based on the structure, size, and charge of the analytes, 
separation is achieved through the difference in their affinities for the two phases. SPE can be 
carried out by four different mechanisms—reversed phase, normal phase, ion exchange, and 
through “molecular recognition” using molecularly imprinted polymers (MIPs). 
   In reversed phase SPE (hydrophobic phase SPE), the sorbent stationary phase is non-polar, 
and is composed of a silica or polymer backbone modified with an alkyl or aryl group [22, 33]. 
Reversed phase SPE is usually used to extract relatively non-polar, charge-neutral compounds 
from complex matrices.  Retention occurs due to hydrophobic (non-polar) interactions between 
the C–H bonds of the analytes and the C–H bonds of the modified sorbent [33]. Due to its 
selectivity, C18 is the most widely used sorbent. 
In normal phase SPE (hydrophilic phase SPE), the sorbent stationary phase is polar, and is 
composed of a silica backbone bonded with carbon chains containing polar functional groups 
[22]. Normal phase SPE is usually utilized for extracting analytes with polar groups, such as 
amines, hydroxyls, and carbonyls [22, 33]. The retention of these polar compounds occurs due to 
hydrophilic (polar) interactions, including hydrogen bonding, pi-pi, or dipole-dipole interactions, 
between the functional groups of the analytes and those of the modified sorbent [22, 33]. 
In ion-exchange SPE, sorbents are composed of a silica backbone bonded with carbon chains 
terminated by positively or negatively charged functional groups. Thus, ion-exchange SPE may 
be cation, anion, or copolymeric mixed-mode (MM) ion-exchange. 
In cation-exchange SPE, sorbents are composed of a silica backbone bonded to a carbon chain 
terminated by negatively charged functional groups, such as benzenesulfonic acid (strong), 
propylsulfonic acid (strong), and carboxylic acid (weak). In this separation technique, analytes 
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are manipulated to carry a positive charge by adjusting the pH of the aqueous solution to 
completely ionize the analytes [22]. Thus, the negatively charged functional groups of sorbents 
interact with the positively charged functional groups of analytes. Generally, these extracted 
analytes are amine-containing compounds or positively charged metal ions [22, 33].  
In anion-exchange SPE, positively charged functional groups, such as primary and secondary 
amine (weak), aminopropyl (weak), diethylamino (weak), and quaternary amine (strong), are 
present on carbon chains bonded to the silica backbone of the sorbent. In this technique, the 
analytes are manipulated to carry a negative charge, which then form strong bonds with the 
positively charged functional groups of sorbents [22]. This may be done by changing the pH of 
the solution to completely ionize the analytes. Typically, analytes containing phosphate, 
carboxylic acid, and sulfonic acid groups are separated by this method [22, 33]. 
In copolymeric MM ion-exchange SPE, sorbents interact with analytes by forming both 
hydrophobic and ionic bonds. These sorbents are composed of a silica or polymeric backbone 
bonded to alkyl functional groups (hydrophobic interaction), and amine or acid functionalities 
(ionic interaction). This technique is widely used to analyze drugs of abuse because of its ability 
to extract a wide range of components simultaneously; acidic, neutral, and basic polar 
compounds can be separated on the same column. Analyte-selective aqueous washing solvents 
and appropriately selected eluting solvents yield clean extracted samples. 
MIPs contain highly selective binding sites for analytes with specific structural features [34]. 
Accordingly, MIPs have been recommended for the extraction of target analytes and to minimize 
Matrix effects (MEs) while providing desirable reagent pH stability. Sorbents in this method are 
synthesized by combining a template molecule solution of monomer and a cross-linking agent, 
which induces the formation of a rigid polymer around the template. After removing the 
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template, the polymer with analyte-selective cavities or imprints is obtained. Due to the 
complementary shape of the polymer and other physicochemical properties, such as hydrogen 
bonding or ionic and hydrophobic interactions, analytes of interest are retained on these sorbents. 
However, a key limitation of MIPs is the detection of residual template molecules from the 
polymerized sorbent matrix by a highly sensitive instrument. 
Analyte extraction by SPE includes five steps—conditioning, equilibration, loading, washing, 
and elution. Conditioning is performed to wet the porous surfaces of the stationary phase and to 
facilitate the adsorption of analytes on the sorbent. This step is carried out by using organic 
solvents, such as MeOH [33]. Equilibration is performed to displace MeOH in the pores by using 
aqueous buffer solvent to allow the analytes of interest to interact with the sorbent [22, 33]. A 
pretreated sample in the same buffer solvent used in the equilibration step, is then loaded onto 
the sorbent and allowed to flow under gravity [22]. In the washing step, matrix constituents and 
impurities that may interfere with the analysis are removed by a series of washing solvents 
owing to their poor retention affinity towards the sorbent [22]. The sorbent is then dried by 
vacuum to remove any residual solvent or water after washing [22]. Elution is performed using a 
strong solvent to break the interaction between the analyte and the sorbent [22]. Table 2 shows 
the advantages and disadvantages of SPE. 
 
Table 1: Advantages and disadvantages of liquid-liquid extraction (LLE) 
Advantages  Disadvantages 
- Easy to remove inorganic salts - Labor-intensive work 
- Rapid method development  - Requires large volumes of solvents 
- Low cost - Difficult to be automated 
 - Formation of emulsion 
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Table 2: Advantages and disadvantages of solid phase extraction (SPE) 
Advantages  Disadvantages 
- Highly selective - Greater complexity 
- Highly effective with complex matrices - Time-consuming method development 
- High recovery - Costly 
- High reproducibility 
- Conducive to automation 
 
1.6 Instrumental Analysis of Drugs in Forensic Toxicology 
Drug analyses in forensic toxicology are performed to identify the use of drugs of forensic 
relevance or whether the subject was under the influence of certain drugs during a particular 
period [36]. Results of these analyses must be accurate and reliable to avoid any false positive or 
false negative results that could lead to severe consequences. Therefore, the utilization of highly 
sensitive and selective hyphenated analytical techniques, such as gas chromatography-mass 
spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS), is necessary to 
qualitatively and quantitatively analyze drugs in WB samples [37]. 
1.6.1 Gas Chromatography-Mass Spectrometry (GC-MS) 
GC-MS is an advanced analytical technique that couples the separation capability of GC with 
the detection properties of MS to identify unknown compounds in a sample [38]. Volatile and 
thermally stable analytes are separated by GC; MS relies on the ionization and fragmentation of 
samples compounds to identify their chemical compositions based on the pattern of fragment 
mass-to-charge ratios (m/z). The addition of another mass analyzer to GC-MS increases its 
detection sensitivity and selectivity, leading to the superior configuration known as gas 
chromatography-tandem mass spectrometry (GC-MS/MS) [38].  
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Separation by GC is initiated by volatilizing the sample by rapid exposure to a high 
temperature zone (200–300°C) and mixing with a stream of carrier gases, such as Ar, He, N2, or 
H2 (mobile phase). The resulting gas mixture reaches the chromatographic column (separation 
zone), which is composed of a fused-silica tubular capillary coated internally with a thin polymer 
film (stationary phase) [39, 40]. Analyte molecules are partitioned between the stationary phase 
and the mobile phase during their movement through the column, and the degree of partition of 
the analytes depends on their chemical structures [40]. At the end of the separation zone, the 
sample is pumped through the sample inlet of a mass spectrometer.  
The mass spectrometer is usually composed of the following four components: a sample inlet, 
an ion source, a mass analyzer, and a detector. The sample inlet is the entry port through which 
the sample is introduced into the instrument. In GC-MS, the sample inlet of the mass 
spectrometer is interfaced with the GC, where a gaseous sample is fed into the instrument to 
reach the ion source [39]. In the ion source, analytes are ionized either by electron ionization (EI) 
or chemical ionization (CI), and are directed to the mass analyzer. By adjusting the electric field, 
only a particular ion with a particular m/z is allowed to reach the detector where the mass 
spectrum is recorded [39, 40].  
GC-MS is considered the “gold standard” in the analysis of volatile and heat-stable 
compounds in modern forensic toxicology because of the availability of extensive libraries for 
spectral matching-based identification [38-41]. The need for chemical derivatization of non-
volatile, polar, and thermally labile analytes to make them sufficiently volatile for GC-MS is 
labor-intensive and costly, thereby limiting the utility of this technique [39, 41–44]. 
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1.6.2 Liquid Chromatography Mass Spectrometry (LC-MS) 
LC-MS is the most advanced analytical technique utilized in contemporary forensic 
toxicology to identify the presence of drugs in biological samples. It overcomes most of the 
limitations of GC-MS, and improves the practicality and reproducibility of highly complicated 
MS analyses [15]. This hyphenated technique exists with single stage MS, (i.e., LC-MS) or with 
tandem MS processes (LC-MS/MS). In LC-MS, low-resolution molecular-mass-selective 
detecting devices, such as a single quadrupole or an ion trap, are coupled with LC. These single 
stage LC-MS platforms have been found to offer limited selectivity for quantifying target 
analytes in complex biological matrices, such as WB [15]. Although time-of-flight mass 
analyzers in single-stage LC-MS offer high selectivity due to their high mass resolution, which is 
a prerequisite for most quantitative assays, they display limited linearity [15, 45, 46]. 
Interestingly, the introduction of MS/MS, which includes two mass filters coupled to a collision 
cell, overcomes this limitation of LC-MS because the analytes of interest can be monitored in 
multiple reaction monitoring (MRM) and their fragmented ions are directly used for analyte 
quantification [15, 45, 46]. 
Analytes are separated by LC as the mobile phase is passed under high pressure through a 
column packed with sorbent materials (stationary phase) having particular physiochemical 
properties; analytes are separated due to differences in their affinities towards the stationary 
phase. The following two separation techniques exist: high-performance LC (HPLC) and ultra-
performance LC (UPLC). In HPLC, the mobile phase is pumped at high pressures up to 5,800 
psi (400 bar) through a column packed with particles having diameters of 3–5 µm with porous 
shells of 0.25–0.5 µm in thickness [47–49]. In UPLC, the mobile phase is continuously pumped 
at high pressures up to 15,000 psi (1,034 bar) with low dispersion through a column packed with 
particles having diameters less than 2 µm [49]. UPLC has a higher separation power than HPLC, 
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and facilitates the separation of multiple analytes in a short runtime [50]. Eichhorst et al. 
separated 42 compounds within a run time of 5.2 min [51]. This separation power is a result of 
the reduction in stationary phase particle diameter. The Van Deemter equation is an empirical 
equation used to mathematically depict the relationship between linear velocity (flow rate) and 
height equivalent to theoretical plate. 
 
 
H =A + (
B
µ
) + C × µ 
 
 
(1) 
 
H, height of a theoretical plate 
µ, average linear velocity of the mobile phase 
A, eddy diffusion term 
B, longitudinal diffusion term 
C, mass transfer term 
 
Hence, chromatographic column performance can be evaluated by the Van Deemter curve 
(see Figure 2) because particle size influences the mass transfer term in the equation [52, 53]. 
Therefore, particle sizes less than 2 µm would not only significantly increase the separation 
efficiency, but also allow stable separation at increased flow rates or linear velocities.  
Certain applications may call for extended runtimes in UPLC. The separation of structurally 
isomeric analytes requires an extended runtime to ensure full baseline resolution of the analytes, 
especially when they yield the same fragment ions. In such an analytical assay, mobile phase 
composition is maintained isocratic (constant mobile phase composition) or “pseudo-isocratic”, 
where the mobile-phase composition gradient is extremely shallow [54,55]. Chołbiński et al. 
reported an isocratic method to resolve amphetamine (AMP) from its structural isomer, beta-
methylphenethylamine (BMP), using UPLC-MS/MS with a runtime of 9.5 min [56]. 
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Analyte separation in UPLC starts when the sample is introduced through an injector into the 
continuously flowing stream of mobile phase that delivers the sample to the UPLC column; the 
column is packed with the stationary phase [57]. By partitioning between the stationary phase 
and the mobile phase, analyte molecules are separated from each other as they move through the 
column based on differences in their partition coefficients between the two phases. [40]. 
After the analytes are separated by UPLC, they are introduced into the mass spectrometer 
through the interfaced sample inlet, which carries the separated analytes to the ion source. 
Ionization is commonly achieved using electrospray ionization (ESI), and can be performed in a 
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 Figure 2: Van Deemter curve 
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negative or positive mode depending on the chemical properties of the analytes. In ESI, the 
liquid eluent is pumped through to a heated, charged capillary, which is surrounded by 
nebulizing inert gas channels that help in forming fine charged droplets [37, 58]. These droplets 
are evaporated by a desolvation (cone) gas that results in a decrease in droplets size and an 
increase in charge density [37]. The size of the charged droplets decreases continuously until the 
charge transfers to the solutes, which then move to the mass analyzer. Mass analyzers sort ions 
according to mass to charge ratio (m/z), prior to ions reaching the detector, where the mass 
spectrum is recorded [37]. Figure 3 shows a schematic diagram of the ESI process in the positive 
ion mode [59].  
UPLC-MS differs from UPLC-MS/MS in the number of mass analyzers; UPLC-MS/MS has 
two mass analyzers, whereas UPLC-MS has only one mass analyzer. Figure 4 shows a schematic 
diagram of an example of a MS/MS configuration (qTOF) [60]. 
 
 
 
Figure 3: Schematic diagram of electrospray ionization in the positive ion mode [59] 
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Figure 4: Schematic diagram of tandem mass spectrometry [60] 
1.7 Stimulant Drugs in Forensic Toxicology 
 
Forensic toxicological analysis deals with a wide range of therapeutic and abused drugs, many 
of which are controlled substances that are consumed for their psychoactive effects, and may 
result in drug addiction or dependence [61]. They may be central nervous system (CNS) 
depressants or stimulants. Depressants are psychoactive drugs that temporarily slow down 
activity of the brain and CNS. Opiates, barbiturates, benzodiazepines, and alcohol are examples 
of CNS depressants [62]. However, CNS stimulants are drugs that have sympathomimetic 
effects, which temporarily increase the activity of the brain and CNS. These drugs include 
amphetamines (AMPs) and cocaine [63]. AMPs are stimulant drugs that possess similar structure 
and functions of endogenous amines, such as dopamine [14]. These sympathomimetic drugs are 
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composed of a phenyl ring connected to an amine group through a two-carbon side chain bearing 
a methyl group. Figure 5 shows the chemical structures of endogenous monoaminergic 
neurotransmitters and the most common ARDs. 
ARDs include a wide range of compounds, such as methamphetamine (MAMP), beta-
methylphenethylamine (BMP), ephedrine (EPH), pseudoephedrine (PEPH), norephedrine 
(NEPH), norpseudoephedrine or cathine (CAT), methylenedioxyamphetamine (MDA), 
methylenedioxymethamphetamine (MDMA), methylenedioxyethylamphetamine (MDEA), and 
phentermine (PHE). These compounds release catecholamines, such as dopamine, from the 
presynaptic cleft at both the central and peripheral sites [14]. The abusive potential of these drugs 
is associated with their psychoactive activity, due to the elevation in dopamine concentrations in 
the shell region of the nucleus accumbens of the ventral striatum [64]. 
1.7.1 Properties of Amphetamine-Related Drugs 
ARDs are a distinct class of sympathomimetic compounds. Based on their origin, they can be 
categorized into synthetic (AMP, BMP, MAMP, MDA, MDEA) and naturally-occurring ARDs 
(EPH, PEPH, NEPH, and CAT) [65]. In this study, a mixture of synthetic and naturally-
occurring ARDs, such as AMP, BMP, CAT, EPH, NEPH, and PEPH, has been chosen based on 
their epidemiological abuse in Saudi Arabia. Structurally, two pairs of these analytes are 
diastereomers (EPH and PEPH; NEPH and CAT), and one pair represents positional isomerism 
(AMP and BMP). Pharmacologically, these sympathomimetics induce the release of 
catecholamines, such as dopamine, serotonin, and noradrenaline [66]. Figure 6 shows the 
chemical structures of the ARDs selected in this study. 
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Figure 5: Chemical structures of endogenous monoaminergic neurotransmitters and examples of 
common amphetamine-related drugs  
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Figure 6: Chemical structures of amphetamine-related stimulants included in this study 
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1.7.1.1  Amphetamine 
AMP was firstly discovered by a Romanian chemist, Lazar Edeleanu, in 1887. It acquired its 
generic name from the contraction of alpha-methyl-phenethyl-amine [67]. Chemically, it exists 
as two optically active enantiomers of α-methyl-phenethyl-amine (Figure 7). These two isomers 
are S-(+)-AMP or dextro-AMP (d-AMP) and R-(-)-AMP or levo-AMP (l-AMP); d-AMP is three 
to four times more potent than l-AMP with regard to CNS stimulation, whereas l-AMP is more 
potent than d-AMP with regard to peripheral nervous system (PNS) [66, 67]. Pharmacologically, 
AMP is one of the most effective sympathomimetic amines that stimulates the CNS [66]. It 
effectively stimulates the CNS because it is structurally similar to endogenous catecholamine 
neurotransmitters (noradrenaline and dopamine) as shown in Figure 6 [66]. AMP 
pharmacokinetics and pharmacodynamics are characterized by its ability to cross the blood-brain 
barrier to release monoamine neurotransmitters from nerve endings. It is considered as a 
prototype and reference drug to which the stimulant effects and potencies of other ARDs can be 
compared [66–69]. AMP is used in the treatment of attention deficit hyperactivity disorder 
(ADHD), narcolepsy, and obesity due to its unique mechanism of action in which dopamine is 
released and its reuptake is inhibited [66–69]. 
1.7.1.1.1 Mechanism of Action 
AMP increases the release of dopamine, norepinephrine (noradrenaline), and serotonin. It acts 
as a potent CNS stimulant by elevating extracellular dopamine levels and prolonging dopamine 
signaling in the striatum through the following three mechanisms: 1) it competes with dopamine 
to bind to the dopamine transporter, leading to the inhibition of dopamine reuptake by dopamine 
transporter; 2) it eases the transport of dopamine from the vesicles to the cytoplasm; 3) it 
facilitates dopamine transporter-mediated reverse transport of dopamine into the synaptic cleft, 
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without necessitating action potential generation for inducing its vesicular release [69, 70]. AMP 
also inhibits monoamine oxidase activity, which is the enzyme responsible for breaking down 
dopamine in the cytosol. Dberkow et al. have demonstrated that both the in vivo and in vitro 
acute effects of AMP are related to its dose, and AMP could work as a dopamine reuptake 
inhibitor at low concentrations, whereas it releases dopamine at high concentrations [71]. 
Accordingly, AMP is used at low doses for its therapeutic effects and at high doses for its 
abusive effects. 
1.7.1.1.2 Intoxication Symptoms 
AMP is clinically used to suppress appetite, treat narcolepsy, and manage ADHD. However, 
its use is associated with adverse effects, such as insomnia, weight loss, and anorexia. In a study 
carried out in 2001 by James et al, the adverse effects of using d-AMP in the management of 
ADHD in children included insomnia, nightmares, anxiety, biting of fingernails, poor appetite, 
and euphoria [72]. Other adverse effects of using AMP for therapeutic purposes include 
abdominal cramps, nausea, vomiting, hypertension, and tachycardia [72–77]. 
Abusively high doses of AMP are associated with serious adverse effects, such as paranoia, 
hallucinations, panic attacks, and violence. These effects gradually increase with the frequency 
of AMP abuse. In 1996, Hall et al. found that the most common adverse effects of AMP were 
depression (79%), anxiety (76%), paranoia (52%), hallucinations (46%), and violent behavior 
(44%) among young adults in Sydney, Australia; their intensities and incident frequencies 
correlated with the route of administration of AMP [79]. The magnitude of the adverse effects 
depends on various factors, such as dose, route of administration, tolerance, and reactivity of 
AMP with other drugs. 
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1.7.1.1.3 Pharmacokinetics of AMP 
Typically, AMP has a high oral bioavailability, a moderate volume of distribution (4 L/kg), 
and exhibits low plasma protein binding (< 20%). It is extensively metabolized in the liver, and 
eliminated from the liver and kidneys with an elimination half-life of 6–12 h. AMP is a basic 
drug (pKa 9.9) with a relatively low molecular weight, which allows it to easily cross lipophilic 
cellular membranes [81]. 
AMP is commonly administered orally in the form of d-AMP or as a racemic mixture (d, l-
amphetamine sulphate). The peak plasma concentration (Cmax) is generally attained within 4 h of 
oral ingestion (tmax). Area under the plasma concentration-time curve after 24 h of administration 
(AUC0–24) and Cmax are proportional to the ingested dose, and do not differ for the two isomers of 
AMP [81–83]. Table 3 shows the pharmacokinetic parameters of AMP in humans after single 
oral administration [81]. 
AMP exhibits low protein binding; therefore, most of the AMP available in the plasma can 
diffuse into the extracellular compartment. Accordingly, amphetamine-dependent individuals, 
who are tolerant to AMP, exhibit a larger volume of distribution (6.1 L/kg) than drug-naïve 
individuals (3.2 L/kg). This difference in AMP distribution can be explained by the higher tissue 
affinity to AMP in those who are tolerant. Tissue affinity to AMP increases because of altered 
pharmacokinetic tolerance and tissue sequestration. The protein binding and volume of 
distribution of d- and l-AMP enantiomers are similar (Table 3) [81, 83, 84]. 
AMP is metabolized by N-deamination and oxidation into benzoic acid derivatives, which 
further conjugate with glycine to form hippuric acid derivatives. It is also metabolized through 
aromatic C-4 hydroxylation to 4-hydroxyamphetamine, which is further conjugated with 
sulphate or glucuronic acid [81–83]. AMP also undergoes hydroxylation to form a reactive 
intermediate, which can further react with glutathione to form a (glutathione-S-yl)-p-
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hydroxyamphetamine adduct [81, 85]. The formation of NEPH occurs through a minor metabolic 
pathway in which the -carbon of the side chain is oxidized. The aromatic ring of NEPH is 
further oxidized to form hydroxynorephedrine [81, 86]. These metabolic pathways of AMP 
appear to be catalyzed by CYP450 isoenzymes; the CYP2C and CYP2D6 subfamilies catalyze 
the N-deamination and aromatic ring hydroxylation, respectively. Figure 8 shows the metabolic 
pathway of AMP [81, 86–88]. 
AMP undergoes extensive excretion by the kidneys. The plasma half-life of AMP is, to a 
certain extent, dependent on urine pH. Because AMP is a weak base, its renal excretion increases 
with acidic urine and decreases with alkaline urine [81, 88-94]. Therefore, the elimination half-
life of AMP has a wide variability; it has a plasma elimination half-life of 6–12 h. This 
elimination half-life was found to be longer in AMP-dependent individuals than drug-naïve 
individuals (21.8 ± 1.4 vs 13.9 ± 3.4 h in alkaline urine) at the same oral dose of 25 mg (Table 3) 
[81, 82, 84]. The elimination half-life of AMP is found to be independent of its route of 
administration, and tends to be longer in AMP abusers [81, 85].  
 
 
 
Figure 7 : Chemical structures of the enantiomers of amphetamine 
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Figure 8: Metabolic pathways of amphetamine 
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Table 3: Pharmacokinetic parameters of amphetamine in humans after single oral administration 
Adopted from [81, 82, 83] 
CPmax, maximum plasma concentration; CUmax, maximum urinary concentration; tPmax, time to maximum plasma concentration; tUmax, time to maximum urinary concentration; AUC0–24, area under 
the plasma concentration-time curve from 0 to 24 h after administration; Vd, volume of distribution; T1/2, terminal elimination half-life; Ae (%) amount excreted in urine within 24 h expressed as % of 
ingested dose. 
a n = 2 (individual values) 
b n = 2 (mean ± SD) 
c n = 2 (mean ± SEM) 
d 
AUC from 0 to 4 h after administration 
e 
Isomer studied 
f 
Approximate value 
Dose (mg) n Isomer 
𝐂𝐏𝐦𝐚𝐱 
(ng/mL) 
𝐂𝐔𝐦𝐚𝐱 
(ng/mL) 
𝐭𝐏𝐦𝐚𝐱 (h) 𝐭𝐔𝐦𝐚𝐱 (h) 
𝐀𝐔𝐂𝟎−𝟐𝟒 
(ng*h/mL) 
Vd (L) 𝐓𝟏/𝟐𝛃 (h) Ae (%) Reference 
            
20 2 Racemate (36.6–38.8)a  (3–2)  (482.5–431.6)    68 
30 2 Racemate (57.3–57.8)a  (3–2)  (790.2–753.1)     
35 2 Racemate (63.5–57.5)a  (2–2)  (822.9–758.6)     
40 11 Racemate (69.1–5.7)b  2.2 ± 1.0  (945.4 ± 71.8)     
            
0.25 (mg/kg) 7 S 39.6 ± 2.8b  3      89 
0. 5 (mg/kg) 8 S 67.3 ± 5.4b  4       
            
0. 06 (mg/kg) 12 S 18.3 ± 1.4b  1.9 ± 0.2  49.4 ± 3.4d    90 
0. 10 (mg/kg) 12 S 21.4 ± 0.7b  2.5 ± 0.3  58.3 ± 2.3d     
            
10  (with NaHCO3) 4 Racemate 20f  (Re)  4𝑓   237.6 ± 26.9 17.0 ± 1.5  91 
   20f  (Re)  4
𝑓   243.4 ± 29.0c 23.7 ± 3.5   
10  (with NH4Cl) 4 Racemate 18f  (Re)  4𝑓   210.3 ± 51.3c 6.8 ± 1.0   
   17f  (Re)  4
𝑓   248.1 ± 78.3c     7.7 ± 1.0   
10  (with NaHCO3) 4 S 40f  (Re)  2.5𝑓   258.1 ± 32.7c 15.6 ± 1.3   
  R 40f  (Re)  3
𝑓   267.4 ± 38.1c     25.0 ± 2.3   
            
10  (with NH4Cl) 7 S  1,635.7 ± 1091.0b  4.9 ± 3.0    44.0 ± 6.7 92 
10  (with NH4Cl) 6 S  2,508.3 ± 493.1b  5.3 ± 3.9    41.9 ± 4.8  
10  (with NH4Cl) 7 S  3,308.6 ± 1212.5b  9.7 ± 7.1    34.7 ± 5.2  
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1.7.1.2 -methylphenethylamine  
BMP is a recreational drug that was synthesized in 1930 as an alternative analog of AMP [95, 
96]. BMP is a positional isomer of AMP. Figure 9 shows the chemical structures of AMP and 
BMP [96]. BMP exists as two optically active enantiomers of -methylphenethylamine; they are 
R-(+)-BMP or dextro-BMP (d-BMP) and S-(-)-BMP or levo-BMP (l-BMP). Figure 10 shows the 
chemical structures of these BMP enantiomers. Pharmacologically, BMP acts as a dopamine 
receptor agonist, facilitating dopamine release and inhibiting dopamine reuptake from the 
synaptic cleft; however, several studies carried out on cats and dogs between 1930 and 1940 
found that BMP has a lower potency than AMP in terms of anti-hypotensive activity. 
Nevertheless, BMP was found to be a better bronchodilator than AMP [95-102]. Studies on rats 
showed that BMP crosses the blood-brain barrier [103]. However, only one animal study has 
been carried out to investigate the CNS stimulation effects of BMP [104]. Interestingly, studies 
on its pharmacokinetics, safety, and efficacy in humans and animals are limited [96]. The FDA 
banned its use in dietary supplements and weight-loss products after it was found in multiple 
supplemental products labelled as containing extracts of Acacia rigidula and Acacia arabica 
[96]. To date, no study on BMP pharmacokinetics has been conducted on humans or animals. 
Hence, one of the main goals of this project was to investigate the metabolites of BMP in rats. 
 
  
Figure 9: Chemical structures of amphetamine and -methylphenethylamine 
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Figure 10: Chemical structures of beta-methylphenethylamine isomers 
 
1.7.1.3      Ephedrine 
EPH is a natural sympathomimetic amine that occurs in many Ephedra plant species [94]. It 
was first isolated in the late 18th century, and first synthesized in 1920 in Japan [105, 106]. 
Chemically, EPH exists as two optically active enantiomers of phenylpropanolmethylamine. 
These isomers are (1S,2R)-(+)-EPH (d-EPH) and (1R,2S)-(-)-EPH (l-EPH) as shown in Figure 
11; l-EPH is more potent than d-EPH with regard to its β-adrenergic agonistic action. l-EPH is a 
naturally occurring compound that was found to have a pronounced peripheral and mild central 
stimulant effects [94]. Clinically, EPH is used as a medication for asthma, nasal congestion, and 
obesity [107]. Pharmacologically, EPH induces the release of norepinephrine, from the vesicles 
of sympathetic neurons, so that they can directly interact with alpha- and beta-adrenergic 
receptors [108]. 
1.7.1.3.1     Mechanism of Action 
The stimulation effect of EPH is a result of its direct and indirect activation of alpha- and 
beta-adrenergic receptors [109, 110]. It indirectly activates these receptors by inducing the 
release of norepinephrine from peripheral sympathetic neurons and inhibiting their neuronal 
reuptake [109, 110]. l-EPH exerts indirect sympathomimetic effects similar to those caused by 
28 
 
AMP, albeit to a lesser extent. Because of its similarity to AMP, EPH crosses the blood-brain 
barrier and releases epinephrine and dopamine in the substantia nigra at high doses [111]. 
1.7.1.3.2     Intoxication Symptoms 
The intoxication symptoms of EPH can be categorized into two categories. The first category 
deals with the therapy-related adverse effects of EPH, including hypertension, headache, 
palpitation, sweating, weakness, tremors, myocardial infarction, seizures, and stroke [94, 105, 
107–110]. The second category focuses on adverse effects associated with EPH overdose; these 
are similar to those of AMP and include paranoia, delusions, hallucination, and hostile behavior 
[94, 112, 113]. 
1.7.1.3.3     Pharmacokinetics of EPH 
EPH exhibits high bioavailability. It is a basic drug (pKa 9.6) with relatively low molecular 
weight; therefore, it easily crosses lipophilic cellular membranes [94, 114]. EPH can be orally, 
intravenously, or intramuscularly administered in the form of (1R,2S)-(-)-EPH enantiomer (l-
EPH) or as a racemic mixture (d,l-ephedrine sulphate or hydrochloride). Plasma Cmax is generally 
attained within 2 h (tmax) of oral ingestion. EPH exhibits a volume of distribution of 2.4–3.6 L/kg 
[94, 114–116]. It is mainly metabolized in the liver by N-demethylation to NEPH (catalyzed by 
CYP450 isoenzymes). It also undergoes p-hydroxylation and conjugation [94]. Figure 12 shows 
the main metabolic pathway of EPH. It is mainly eliminated by renal excretion, and its plasma 
half-life is, to a certain extent, dependent on urine pH. Being a basic drug, it is rapidly excreted 
in acidic urine [94,114]. This explains the wide variability in its elimination half-life, which is 
found to be 4–10 h [94]. Table 4 shows the pharmacokinetic parameters of EPH in humans after 
single oral administration [114].  
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Figure 11: Chemical structures of ephedrine isomers 
 
 
 
 
Figure 12: Main metabolism pathway of ephedrine  
 
1.7.1.4 Pseudoephedrine 
PEPH is a naturally occurring alkaloid in various Ephedra plant species [94]. PEPH was 
firstly isolated in 1889 by Ladenburg and Olschlägel [122, 123]. Chemically, PEPH is a 
diastereomer of EPH, and exists in two optically active enantiomers of phenyl 
propanolmethylamine; they are (1S,2S)-(+)-PEPH (d-PEPH) and (1R,2R)-(-)-PEPH (l-PEPH) as 
shown in Figure 13. PEPH is a naturally occurring sympathomimetic amine that has pronounced 
peripheral and mild central stimulant effects; however, it has lower potency than EPH with 
regard to its β-adrenergic agonistic action [124]. Clinically, PEPH is used as a nasal decongestant 
and bronchodilator [94]. Pharmacologically, PEPH induces the release of norepinephrine, which 
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is stored in the vesicles of sympathetic neurons, so that it can directly interact with alpha- and 
beta-adrenergic receptors; PEPH interacts with beta-adrenergic receptors to a lesser extent than 
EPH [124]. 
 
 
Table 4: Pharmacokinetic parameters of ephedrine in human volunteers* 
Subject No. 
Body Weight  
Kg 
𝒕𝒎𝒂𝒙  
(h) 
𝐂𝐦𝐚𝐱 
(ng/mL) 
𝒕𝟏
𝟐
 
(h) 
AUC 
(ng · h/mL) 
CL/F 
(L/h · kg) 
V/F 
(L/kg) 
C𝐋𝐑 
(L/h · kg) 
         
1 78.6 2.0 49.5 4.65 537.9 0.41 2.14 0.14 
2 68.1 2.0 69.0 7.25 947.9 0.27 2.18 0.20 
3 52.0 4.0 63.4 8.18 1000.4 0.33 3.06 0.19 
4 76.2 4.0 58.1 5.62 748.7 0.30 1.92 0.12 
5 56.8 2.0 77.2 4.90 727.2 0.42 2.31 0.33 
6 72.7 2.0 51.6 5.32 517.9 0.46 2.75 0.20 
7 54.6 1.5 80.0 5.51 950.3 0.33 2.07 0.25 
8 88.9 1.5 59.5 7.0 645.0 0.30 2.38 0.23 
Mean — 2.4 63.5 6.06 759.4 0.35 2.35 0.21 
SD — 1.0 11.2 1.26 189.6 0.07 0.38 0.07 
         
*Dose of 17.3 mg 
Adopted from [114] 
tmax, time after dosing to maximum plasma concentration; Cmax, maximum plasma concentration achieved 
after a single oral dose; t1/2, elimination half-life; AUC, area under the plasma concentration-time curve; 
CL/F, clearance divided by bioavailability; V/F, apparent volume of distribution; CLR, renal clearance.  
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1.7.1.4.1     Mechanism of Action 
The stimulation effect of PEPH is a result of its direct interaction with alpha-adrenergic 
receptors in the mucosa of the respiratory tract [124]. This direct interaction leads to 
vasocontraction and decreases nasal congestion. PEPH has lesser effectiveness on beta-
adrenergic receptors than EPH because of the differences in their structural configurations; 
consequently, it exerts lower bronchodilator and pressor effects than EPH [124]. At high doses, 
the action of PEPH was found to be mediated by the release of dopamine and the activation of 
dopamine receptors [125]. 
1.7.1.4.2     Intoxication Symptoms 
The symptoms of PEPH intoxication include headache, dizziness, palpitations, tachycardia, 
restlessness, tremor, anxiety, insomnia, dyspnea, hallucinations, pallor, weakness, convulsions, 
arrhythmia, hypotension, and cardiovascular collapse [94, 105, 107–110]. 
1.7.1.4.3     Pharmacokinetics of PEPH 
PEPH has high bioavailability and volume of distribution (2–3 L/kg); it hardly exhibits any 
plasma protein binding (FB=0.20). It is a basic drug (pKa 9.4) with a low molecular weight; 
therefore, it easily crosses lipophilic cellular membranes [94, 114]. It is commonly administered 
orally, and the plasma Cmax is attained within 2 h (tmax) of oral ingestion (Table 5) [94, 114, 126–
128]. Although almost 88% of PEPH is eliminated unchanged, less than 1% is metabolized by 
N-demethylation to norepseudoephrine (catalyzed by CYP450 isoenzymes) [94, 129]. PEPH is 
mainly eliminated by renal excretion, and its plasma half-life is, to a certain extent, dependent on 
urine pH; its excretion rate increases with acidic urine [94,114]. This explains the wide 
variability in its elimination half-life, which is found to be 3–16 h [94]. Table 5 shows the 
pharmacokinetic parameters of PEPH in humans after single oral administration [114].  
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Figure 13: Chemical structures of pseudoephedrine isomers 
 
Table 5: Pharmacokinetic parameters of pseudoephedrine in human volunteers* 
*Dose of 5.3 mg 
Adopted from [114] 
𝐭𝐦𝐚𝐱, Time after dosing to maximum plasma concentration; Cmax, maximum plasma concentration 
achieved after a single oral dose; t1/2, elimination half-life; AUC, area under the plasma concentration-
time curve; CL/F, clearance divided by bioavailability; V/F, apparent volume of distribution; CLR, renal 
clearance. 
Subject No. 
tmax  
(h) 
Cmax 
(ng/mL) 
t1
2
 
(h) 
AUC 
(ng · h/mL) 
CL/F 
(L/h · kg) 
V/F 
(L/kg) 
C𝐋𝐑 
(L/h · kg) 
        
1 4.0 19.4 5.87 245.2 0.28 2.33 0.16 
2 2.0 24.1 6.88 305.5 0.26 2.53 0.23 
3 2.0 23.1 9.83 398.7 0.26 3.62 0.19 
4 4.0 22.1 6.43 323.0 0.22 2.00 0.14 
5 2.0 29.3 4.55 254.8 0.37 2.40 0.32 
6 2.0 22.1 6.00 228.6 0.32 2.76 0.20 
7 1.5 29.1 5.38 318.6 0.31 2.37 0.30 
8 2.0 23.7 5.15 223.8 0.27 1.98 0.25 
Mean 2.4 24.1 6.26 287.3 0.28 2.50 0.22 
SD 1.0 3.5 1.62 60.1 0.05 0.52 0.06 
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1.7.1.5    Norephedrine  
NEPH is a naturally occurring sympathomimetic amine in Khat (Catha edulis Forsk) [134, 
135]. Chemically, NEPH exists as two optically active enantiomers of phenylpropanolamine; 
they are (1S,2R)-(+)-NEPH (d-NEPH) and (1R,2S)-(-)-NEPH (l-NEPH) as shown in Figure 14. 
NEPH is a sympathomimetic alkaloid that is pharmacologically similar to EPH [94]. Clinically, 
NEPH is used to treat nasal decongestion without excessively stimulating the CNS [94, 136, 
137]. NEPH stimulates the sympathetic nervous system either by directly interacting with 
adrenergic receptors or by indirect carrier-mediated exchange with norepinephrine [136]. 
1.7.1.5.1     Mechanism of Action 
The stimulation effect of NEPH is a result of its ability to selectively release norepinephrine 
[135]. Interestingly, NEPH releases dopamine at higher doses [135]. 
1.7.1.5.2     Intoxication Symptoms 
The symptoms of NEPH intoxication include headache, dizziness, palpitations, tachycardia, 
nervousness, anxiety, arrhythmia, insomnia, agitation, tremors, hallucinations, pallor, weakness, 
convulsions, hypotension, and cardiovascular collapse [94]. 
1.7.1.5.3     Pharmacokinetics of NEPH 
NEPH has a high bioavailability. It is a basic drug (pKa 9.1) [94]. It is commonly 
administered orally. The Cmax is generally attained within 2.8 h (tmax) of oral ingestion [94]. Its 
volume of distribution was found to be 4.5 L/kg (Table 8) [94, 138]. In the first 24 h after dosing, 
NEPH is excreted unchanged in the urine with a mean recovery of 97% [94]. Heimlich et al. in 
1961 reported that NEPH forms a p-hydroxy metabolite through a minor metabolism pathway 
(Figure 15) [139]. Its elimination half-life depends on urine pH, and is 3–4.4 h; an acidic urine 
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enhances the execration rate of NEPH, whereas an alkaline urine decreases it [94, 140, 141]. 
Table 6 shows pharmacokinetic parameters of NEPH.  
 
 
  
 
 
Figure 14: Chemical structures of norephedrine isomers 
 
 
 
 
 
 
 
 
 
Figure 15: Minor metabolism pathway of norephedrine 
 
 
 
 
35 
 
Table 6: Pharmacokinetic parameters of norephedrine 
Adopted from [ 138] 
tlag, Lag time until appearance of substance in the central compartment; Cmax, maximal plasma 
concentration; tmax, corresponding time to Cmax; AUC, area under the concentration-time curve (by curve 
integration) 
Parameters 
Participants 
Mean ± SD 
1-Male 2-female 3-female 4- male 
Body weight (kg) 95.0 58.0 59.0 74.0 71.5 ± 17.3 
Khat chewed (g) 59.2 36.1 36.1 43.6 43.8 ± 10.9 
Amount in residue (% of original content) 4.8 5.9 7.2        6.1    6.1 ± 1.0 
Ingested dose (mg) 25.0        15.1         14.9        18.2       18.3 ± 4.7 
𝐭𝐥𝐚𝐠𝟏(h) 0.01 0.20         0.18 0.30 0.17 ± 0.12 
𝐭𝐥𝐚𝐠𝟐(h) 1.03 1.03         0.99 2.22 1.32 ± 0.60 
𝐭𝐦𝐚𝐱 (h) 2.48 2.92 2.56 3.41 2.84 ± 0.42 
Cmax (ng/mL) 76.3 84.2 55.3 72.7 72.0 ± 12.2 
AUC (ng · min/mL) 690 942 525 681 710 ± 173 
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1.7.1.6 Cathine 
CAT, d-norpseudoephedrine, is one of the naturally occurring sympathomimetic alkaloid 
amines in Khat [134, 135]. Chemically, CAT is a diastereomer of NEPH. It exists as two 
optically active enantiomers of phenylpropanolamine; they are (1S,2S)-(+)-CAT (d-CAT) and 
(1R,2R)-(-)-CAT (l-CAT) as shown in Figure 16. d-CAT is a more potent sympathomimetic 
agent than l-CAT [146, 147]. It exhibits 7–10 times lower psychostimulant potency than AMP 
[146]. 
1.7.1.6.1     Mechanism of Action 
CAT is a psychostimulant known for its ability to release norepinephrine (norepinephrine 
agonist) and dopamine (dopamine agonist). At high doses, CAT induces the release of dopamine 
from nerve terminals [146, 147]. 
1.7.1.6.2     Intoxication Symptoms 
The symptoms of CAT intoxication include headache, dizziness, palpitations, tachycardia, 
nervousness, anxiety, arrhythmia, insomnia, agitation, tremors, hallucinations, pallor, weakness, 
convulsions, palpitations, hypertension, vasoconstriction, ischemia, infarction, pulmonary 
edema, and cerebral hemorrhage [94, 148]. It also causes spermatorrhea, impotence, changes in 
libido, and urinary retention [148].  
1.7.1.6.3     Pharmacokinetics of CAT 
CAT has a high bioavailability and a low volume of distribution (0.74 L/kg). It is a basic 
compound (pKa 9.37) [138, 149]. It is commonly orally administered. The plasma Cmax is 
generally attained within 2.6 h (tmax) of oral ingestion. Its elimination half-life (5.22 h) is 
dependent on urine pH (Table 7) [138]. It is excreted unchanged for almost 24 h [150]. Table 7 
shows pharmacokinetic parameters of CAT. 
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Figure 16: Chemical structures of cathine isomers 
 
 Table 7: Pharmacokinetic parameters of cathine 
 Adopted from [ 138] 
tlag, Lag time until appearance of substance in the central compartment; Fabs, absorbed proportion; Cmax, 
maximal plasma concentration; tmax, corresponding time to Cmax; CLtotal/F, apparent total body clearance; 
MRT, mean residence time; AUC, area under the concentration-time curve (by curve integration); Vc/F, 
apparent volume of the central compartment; t1/2α, half-life of the distribution phase; t1/2, terminal 
elimination half-life  
 
 
 
 
Parameters 
Participants 
Mean ± SD 
1-male 2-female 3-female 4-male 
      
Body weight (kg) 95.0 58.0 59.0 74.0 71.5 ± 17.3 
Khat chewed (g) 59.2 36.1 36.1 43.6 43.8 ± 10.9 
Amount in residue (% of original content) 8.0 6.2 17.3 12.3 10.9 ± 5.0 
Ingested dose (mg) 45.4 28.1 24.8 31.7 32.4 ± 8.9 
tlag 1 (h) 0.13 0.001 0.52 0.20 0.21 ± 0.22 
tlag 2 (h) 1.33 1.10 1.07 2.32 1.46 ± 0.59 
Fabs 1 (%) 84 77 92 84 84 ± 6 
Fabs 2 (%) 16 23 8 16 16 ± 6 
tmax (h) 1.65 2.46 2.88 3.49 2.62 ± 0.77 
Cmax (ng/mL) 67.2 87.6 54.6 75.2 71.2 ± 13.9 
AUC (ng · min/mL) 598 881 620 753 713 ± 131 
CLtotal/F (mL min
-1
) 1,250 530 672 710 791 ± 316 
MRT (h) 7.13 10.70 13.30 9.70 10.21 ± 2.55 
Vc/F (L/kg) 1.08 0.67 0.28 0.94 0.74 ± 0.35 
t1/2α (h) 0.08 0.37 0.11 0.41 0.24 ± 0.17 
t1/2 (h) 2.72 4.71 10.10 3.34 5.22 ± 3.36 
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 Table 8: Pharmacokinetic parameters of the amphetamine-related drugs  
 
 
1.8 Detection of Selected ARDs in Whole Blood 
In contemporary forensic toxicology, analyses of selected ARDs in the blood are mainly 
carried out by using GC-MS or LC-MS to prevent doping, detain impaired drivers, stop drug 
abuse at workplaces, and investigate criminal cases (ante- and post-mortem) where drug abuse is 
expected.  
Prior to GC-MS analysis, WB samples must be pretreated to facilitate the extraction of ARDs 
from WB. Due to their polarity, ARDs can be directly analyzed by GC-MS without 
derivatization; however, this direct analytical method is not recommended, particularly for WB 
samples because the fragment ions of ARDs bear similarity with those of other blood 
components, especially in post-mortem WB samples [152]. Therefore, the derivatization of 
Compound  t1/2 (h) V/F (L/kg) FB pKa Reference 
Amphetamine 7-34 3.2–5.6 0.16 9.90 [94] 
Β-methylphenethylamine --- --- --- 10.2 [151] 
Ephedrine 4–10 2.6–3.1 --- 9.6 [94] 
Pseudoephedrine 3.0–16  2.0–3.0 0.20 9.4 [94] 
Norephedrine 3.0–4.4 4.5 --- 9.10 [94] 
Cathine 5.22 0.74 --- 9.37 [138, 149] 
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ARDs is recommended. ARDs can be derivatized by different derivatizing agents, such as 
heptafluorobutyric anhydride, pentafluoropropionic anhydride, trifluoroacetic anhydride, acetic 
anhydride, N-methyl bis (trifluoroacetamide), and 4-carbethoxyhexafluorobutyryl chloride [152–
154]. Derivatization occurs due to the direct interaction of the derivatizing agent with the amine 
group of ARDs. Each one of these derivatized products yields fragmented ions that can be 
chosen to represent all parts of the fragmented compound [152–154]. 
The analytical detection of ARDs in WB by GC-MS was the ideal standard analytical method 
before the emergence of hyphenated LC-MS. Kudo et al. have reported an analytical method for 
qualifying and quantifying 13 ARDs in WB using GC-MS with an enhanced polymer column 
after extracting the analytes from WB using SPE and derivatization by acetalization; this study 
did not focus on resolving isomeric analytes [155]. Table 9 shows the 13 analytes and their limits 
of detection [155]. Furthermore, Kankaanpää et al. developed and validated a rapid GC-MS 
analytical method for 15 ARDs in human blood by extracting and derivatizing the analytes in a 
single step [156]. In this study, PEPH was fully resolved from its diastereoisomer, EPH. 
The extraction of ARDs from WB samples may be challenging for analysis by GC-MS or LC-
MS. If the polarity and volatility of ARDs are not controlled during extraction, they may be lost 
by evaporation or by adsorptive losses to activated glass present in the glass tubes or liners of the 
injection ports. Therefore, samples must be evaporated at 40°C or less during extraction, under 
acidic conditions. Furthermore, all glass apparatus must be deactivated to prevent the reaction of 
the protonated amine groups of ARDs and the silanol groups of glass. [152–154, 157]. 
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     Table 9: Limits of detection of 13 analytes 
     Adopted from [155] 
ARDs can be directly determined by using LC-MS without derivatization. Moreover, LC-MS 
is significantly more sensitive than GC-MS [158]. However, the same analytical challenges 
encountered during GC-MS analysis, such as sample polarity and volatility, also affect LC-MS 
analysis. Furthermore, LC-MS analyses require the samples to be extensively pretreated and 
cleaned up to avoid any MEs that are most likely to interfere with analyses. Although such clean 
samples may be easily obtained in ante-mortem blood samples, an extensively putrefied post-
mortem WB sample can present challenges. Another issue during the analysis of ARDs by LC-
MS is the potential for extensive analyte fragmentation within the ion source chamber of the 
mass spectrometer. These analytical challenges must be overcome to develop and validate an 
No. Compound LOD (ng/mL) 
1 3,4-methylenedioxyamphetamine 7 
2 3,4-methylenedioxymethamphetamine 7 
3 4-methylthioamphetamine 10 
4 amphetamine 7 
5 dimethylamphetamine 7 
6 ephedrine 50 
7 methamphetamine 7 
8 methylephedrine 50 
9 
N-methyl-1-(3,4-methylene dioxyphenyl)-2-
butanamine 
5 
10 phenylpropanolamine 50 
11 p-methoxyamphetamine 7 
12 p-methoxymethamphetamine 50 
13 β-phenethylamine 50 
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analytical assay for the identification and quantification of ARDs in WB by LC-MS. Dalsgaard 
et al. developed and validated an analytical method for the identification and quantification of 30 
drugs in WB by using SPE and UPLC-qTOF-MS [159]. Practically, it is a challenge to obtain a 
fully resolved chromatogram of diastereomers by LC. Therefore, it requires the selection of the 
most suitable type of column, mobile phase, and chromatographic conditions. Accordingly, 
Sørensen described the analysis of cathinones and related ephedrines in forensic WB samples by 
simple extraction methods and LC-MS/MS analyses [160]. In this study, two pairs of 
diastereomers (EPH and PEPH; NEPH and CAT) were studied. These diastereoisomers were not 
fully resolved because of employing gradient elution (Figure 17) [160]. Apollonio et al. reported 
the use of UPLC/MS in the determination of ARDs and ketamine for forensic and toxicological 
analysis [161]. In this study, EPH and PEPH were fully resolved by employing an isocratic 
elution [161]. Table 14 shows LC-MS procedures for the identification and/or quantification of 
ARDs in WB [160–164]. 
Figure 17:  Extracted ion chromatograms of the quantifier ion of norephedrine and cathine 
(top), and ephedrine and pseudoephedrine (bottom); adopted from [160]. 
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1.9 Interpretive Challenges 
The forensic toxicology of ARDs in WB is not only challenging in analytical terms, but also 
in the toxicological interpretation of the measurements. Interpretations must consider several 
factors that can enhance or suppress intoxication symptoms in ante-mortem WB, and 
concentrations in post-mortem cases [165]. 
1.9.1 Drug Tolerance  
Tolerance is a phenomenon in which a drug user is adapted to the effect of that drug. 
Consequently, a higher dose of the drug is required to induce the same effect as that experienced 
when the drug was used for the first time [166]. Tolerant abusers of ARDs require high doses 
that are toxic to naïve individuals.  
There are mainly two types of tolerance; pharmacodynamic and pharmacokinetic tolerance. 
Pharmacodynamic tolerance occurs due to neuroadaptation that reduces the number or sensitivity 
of dopamine, alpha- and beta-adrenergic, and norepinephrine receptors to induce physiological 
responses [166]. Pharmacokinetic tolerance occurs because of decreased quantity of ARDs 
reaching dopamine, alpha- and beta-adrenergic, and norepinephrine receptors. This type of 
tolerance may be caused by increased in enzyme activities that required to metabolize ARDs 
(CYP450 enzymes).  In such cases, intoxication symptoms are masked. Therefore, tolerance is 
an unpredictable phenomenon that challenges the interpretability of blood ARD concentrations 
in relation to behavioral effects, or the prediction of toxicity when the dose, route of 
administration, and time of last dose are not known [165]. Accordingly, the plasma concentration 
of AMP was found to be 590 ng/mL after 1 h of intravenous dl-AMP (160 mg) administration in 
a chronic user [94, 167]. Moreover, the steady-state AMP blood level was 2,000–3,000 ng/mL in 
a tolerant individual abusing AMP at an oral dose of 1000 mg daily [94, 168]. Serum EPH 
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concentration in a user addicted to EPH was 23,000 ng/mL after 1.5 h of ingestion of 7,500 mg 
of EPH [94, 169]. In 10 chronic users of PEPH, the average steady-state plasma concentration 
was 500–640 ng/mL after ingesting 360 mg of PEPH daily for 14 days [94, 129]. In six 
volunteers who orally ingested 150 mg of phenylpropanolamine, the serum concentration peaked 
to 280 ng/mL after 6 h [94, 170]. 
1.9.2 Post-mortem Redistribution 
PMR is one of the major obstacles encountered during the analysis of drug concentrations in 
post-mortem cases [171]. Theoretically, it is defined as the change in drug concentration after 
death [172]. In such cases, drugs redistribute from solid organs (liver, lung, and myocardium) 
into the blood depending on the physiochemical and pharmacokinetic properties of drugs, such 
as volume of distribution, lipophilicity, and pKa [172]. ARDs exhibit PMR due to their high 
volumes of distribution and lipophilicities (Table 8). Consequently, it is necessary to consider 
PMR when interpreting the concentration of ARDs in the post-mortem blood. Failure to account 
for PMR could result in misleading interpretations of the cause of death [172].  
AMP exhibits PMR. Accordingly, AMP concentration ratio in the heart:femoral blood was 
1.5 in three cases [93, 94, 179]. In 17 fatal cases solely attributed to AMP, its concentrations in 
the femoral post-mortem blood were found to be 1,100–7,400 ng/mL [93, 94]. Interestingly, EPH 
was not found to show PMR, although the number of cases studied was small. Dalpe-Scott et al. 
reported that EPH concentration in the heart was equal to that in the femoral blood in three 
separate post-mortem cases [119, 121]. In five cases of death related to voluntary overdose of 
EPH, its concentration in the post-mortem blood was found to be 3,500–21,000 ng/mL [94, 117–
119]. In contrast to EPH, PEPH exhibits PMR. Accordingly, Dalpe-Scott et al. reported that 
PEPH concentration ratio in the heart:femoral blood was 1.5 in three post-mortem cases [120]. In 
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two cases of death in children due to unintentional overdose of PEPH in combination with other 
agents, PEPH concentration in the post-mortem blood was found to be 6,000–13,000 ng/mL [94, 
130, 131]. Reynolds reported a PEPH post-mortem blood level of 66,000 ng/mL in a case of 
PEPH overdose-related death in a child [132]. NEPH is also exhibited post-mortem 
redistribution. Accordingly, Dalpe-Scott et al. reported that the concentrations of NEPH in the 
heart:femoral blood were in the ratio of 2.4 in three post-mortem cases [120]. In two cases of 
death due to NEPH overdose, NEPH concentrations in the post-mortem blood were reported to 
be 2,000–4,600 ng/mL [94, 142-145]. PMR data for BMP and CAT in fatal cases are not 
available. Table 11 show the tissue distribution of AMP, EPH, PEPH, and NEPH in fatal cases.  
1.10 Goals of This Study 
The preliminary goal of this research was to develop and validate a new analytical method for 
identifying and quantifying ARDs in WB by SPE and LC-MS/MS. In this method, WB was 
pretreated by using a precipitation agent in form of an organic solvent (ACN) and extracted by 
MIP-SPE and MMSPE. The extracted samples were analyzed by UPLC-qTOF-MS. Method 
development and validation steps were based on the standard practices of the Scientific Working 
Group for Forensic Toxicology (SWGTOX) [176]. 
The secondary goal of this project was to apply the validated method to analysis of BMP in 
rats, and to attempt to identify BMP metabolite(s). An experimental study employing four groups 
(control, low dose, high dose, and high delayed dose) of rats (ni = 3) was designed. Blood 
samples obtained from the rats were pretreated, extracted, and analyzed according to the 
validated analytical method. 
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Table 10: LC-MS procedures for the identification and/or quantification of ARDs in WB  
LLE, liquid-liquid extraction; LOD, limit of detection; DAD, photodiode array detector; OPA, o-phthalaldehyde, FL, fluorescence. 
 
 
 
 
 
 
 
Compound Sample 
Internal 
Standard 
Extraction Stationary Phase Mobile Phase Detection Mode Validation Data Reference 
         
EPH 
PEPH 
NOR 
CAT 
 
 
Blood 
Norephedrine – D3 
Cathine – D3 
Ephedrine – D3 
Pseudoephedrine – D3 
 
LLE 
   Prodigy Phenyl-3 
(150 x 2 mm I.D., 
5 µm) 
Gradient elution: 
water and MeOH  
acidified with 0.1 
formic acid 
Micromass Quattro 
Micro API triple-
quadrupole 
Recovery: 87-100 % 
LOD:0.5-3 µg/L 
Linearity: 10-250 
µg/L 
[160] 
AMP Blood ---- LLE 
Aluspher RP-select B 
(125 x 4 mm I.D., 
5 µm) 
Gradient elution: 
0.0125 M NaOH  
in MeOH-aqueous 
mM NaOH 
DAD 225–350  [162] 
         
AMP 
Hydroxyamphetamine  
Blood Tryptamine 
LLE, OPA (or 
microdialysates, 
MD) 
Supelco LC18 (250 x 
4.6 mm, I.D., 5 µm)  
Gradient elution: 
Methanol-
potassium 
phosphate buffer  
pH (5.5) 
FL (340/440) 
Recovery: 99 % 
Linearity: 11–460 
ng/ml 
[163] 
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Table 11: Tissue concentrations of amphetamine-related drugs in fatal cases 
Compound  Blood Brain Liver Kidney Urine Gastric Reference 
Amphetamine 
 
Average  
(ng/mL or ng/kg) 
8,600 2,900 3,000 17,000 237,000 ----- 
[93, 94, 179] 
Range  
(ng/mL or ng/kg) 
500–4,100 2,800–3,000 4,300–74,000 3,200–52,000 25,000–700,000 ----- 
Number of Samples 11 2 11 6 8 ----- 
 
β-methylphenethyamine No Data Available  
 
Ephedrine 
Average 
 (ng/mL or ng/kg) 
9,700 8,200 50,000 22,000 262,000 24,000 
[94] 
Range  
(ng/mL or ng/kg) 
3,500–21,000 7,400–8,900 10,000–151,000 14,000–28,000 0–545,000 0–60,000 
Number of Samples 5 5 5 5 5 5 
 
Pseudoephedrine 
Concentration 
 (ng/mL or ng/kg) 
19,000 22,000 33,000 ----- 105,000 102,000 
[94, 133] 
Number of Samples 1 1 1 ----- 1 1 
 
Norephedrine 
Concentration 
 (ng/mL or ng/kg) 
48,000 86,000 460,000 ----- ----- 20,000  
[94, 142] 
Number of Samples 1 1 1 ----- ----- 1 
 
Cathine No Data Available 
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CHAPTER 2 
 
2. Methods 
2.1 Chemicals and Materials 
Standards for (±) amphetamine, (S,S)-(+)-pseudoephedrine, (1S,2R)-(+)-ephedrine-d3 HCl, 
and (±)-amphetamine-d11 were purchased from Cerilliant (Round Rock, TX, USA) as 1 mg/mL 
methanolic solutions and diluted as required. (R*,S*)-(±)-ephedrine HCl, DL-norephedrine, and 
(R)-(+)-β-methylphenethylamine were obtained from Sigma Aldrich (Oakville, Ontario, 
Canada) as 1 mg/mL methanolic solutions and diluted as required. (+)-Norpseudoephedrine 
hydrochloride (cathine hydrochloride) was purchased from LGC Standards (Manchester, NH, 
USA) as a 0.1 mg/mL methanolic solution and diluted as required. ACN, MeOH, and purified 
water, used in drug extraction and UPLC analysis, were of reagent grade and obtained from 
EMD Milipore (Billerica, MA, USA). Ammonium acetate was purchased from Mallinckrodt 
Baker Inc. (Phillipsburg, NJ, USA). Acetic acid and HCl were obtained from BDH (Radnor, PA, 
USA). Ammonium hydroxide, ammonium formate, and formic acid were purchased from Fisher 
Chemicals (Bridgewater, NJ, USA). Amphetamines-specific MIP-SPE (25 mg) was purchased 
from Biotage (Uppsala, Sweden). Mixed-mode SPE (Oasis MCX, 30 mg) and FTPE (HLB 
Prime, 100 mg) were purchased from Waters (Milford, MA, USA). Aged animal blood was 
obtained from Ottawa Laboratory (Nepean, Ontario, Canada). Blank human whole blood was 
obtained from Utak Laboratories Inc. (Valencia, CA, USA). 
2.2 Combined Working Solutions (Neat Standard Mix) 
 Methanolic combined working solutions of the analytes were made at different 
concentrations levels (20, 40, 200, 500, 800, and 1000 ng/mL) for the spiking of drug-free WB, 
and the preparation of calibration standards samples. Three internal standard (IS) solutions 
48 
 
containing 20, 500, 1000 ng/mL of the deuterated analogues of ephedrine and amphetamine were 
also prepared in MeOH for determining MEs 
2.3 Molecularly Imprinted Polymer Solid Phase Extraction (MIP-SPE)  
2.3.1 Whole Blood Sample Pretreatment 
Aliquots (250 μL) of spiked and drug-free WB or aqueous samples were mixed with 1 mL of 
10 mM ammonium acetate (pH 7), followed by an addition of 1 mL of ACN. The mixtures were 
vortexed and centrifuged at 5000 rpm for 15 min at room temperature, and the supernatants were 
decanted into clean tubes. 
2.3.2 Whole Blood Sample Extraction 
The MIP-SPE was carried out on an SPE vacuum manifold. The cartridges were conditioned 
with 1 mL of MeOH and equilibrated with 1 mL of 10 mM ammonium acetate (pH 7). The 
supernatants obtained from the pre-treatment step were loaded under gravity, and the cartridges 
were washed twice with 1 mL of water and once with 1 mL of ACN/water (60:40, v/v). The 
cartridges were then dried for 10 min at -40 kPa, washed with 1 mL of acetic acid/ACN (1:100, 
v/v), and dried again for 30 s at -10 kPa. The analytes of interest were then eluted with 2 mL of 
formic acid/MeOH (1:100, v/v). Figure 18 shows a schematic diagram for the extraction process. 
The eluates were evaporated to dryness under vacuum centrifugation at 30°C, and the residues 
were reconstituted in 200 μL of mobile phase A (5 mM ammonium formate + 0.1% formic acid 
in water). The reconstituted residues were subjected to UPLC-qTOF-MS analysis. Figure 20 
shows the analytical method used in this study. 
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Figure 18: Schematic diagram of MIP-SPE extraction 
2.4 Mixed Mode Solid Phase Extraction (MMSPE) 
2.4.1 Whole Blood Sample Pretreatment 
Spiked and drug-free WB or aqueous samples (250 μL) were mixed sequentially with 1 mL 
each of 0.1 M HCl and ACN. The mixtures were vortexed and centrifuged at 5000 rpm for 15 
min at room temperature, and the supernatants were decanted into clean tubes. 
2.4.2 Whole Blood Sample Extraction 
MMSPE was carried out by using Oasis MCX 96-well plates. The wells were conditioned 
with 1 mL of MeOH and equilibrated with 1 mL of water. The supernatants obtained from the                    
pre-treatment step were loaded under gravity, and SPE wells were washed sequentially with 1 
mL each of 0.1 M HCl, MeOH, and 5% NH4OH. The wells were dried under vacuum (-10 kPa) 
for 10 min, and the analytes were eluted with 1 mL of 5% NH4OH in MeOH (Figure 19). The 
eluates were evaporated to dryness under vacuum centrifugation at 30 °C, the residues were 
50 
 
reconstituted in 200 μL of mobile phase A, and then underwent UPLC-qTOF-MS analysis 
(Figure 20). 
 
Figure 19: Schematic diagram of MMSPE extraction 
 
2.5    Filtration Pass Through Extraction (FPTE) 
2.5.1 Whole Blood Sample Pretreatment 
Drug-free WB or aqueous samples (250 μL) were diluted with 1 mL of MeOH. The mixtures 
were then mixed with 1 mL of ACN. The mixtures were vortexed and centrifuged at 5,000 rpm 
for 15 min at room temperature, and the supernatants were decanted into clean tubes. 
2.5.2 Whole Blood Sample Extraction 
FPTE was carried out by using HLB Prime 96-well plates. The supernatants were directly 
loaded under gravity into the SPE wells. The eluates were collected and evaporated to dryness 
under vacuum centrifugation at 30°C. The dry residues were reconstituted in 200 μL of mobile 
phase A, and submitted for UPLC-qTOF-MS analysis (Figure 20). 
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2.6     UPLC-qTOF-MS Analysis: UPLC Conditions 
Chromatographic separations were obtained on an ACQUITY UPLC™ HSS T3 column (100 
mm × 2.1 mm, 1.8 µm) maintained at 45°C. Mobile phase A consisted of water, 0.1% formic 
acid, and 5 mM sodium formate; mobile phase B was composed of ACN and 0.1 % formic acid. 
The mobile phase composition was controlled as follows: 0–1 min, 0% B; and 1–10 min, 5% B 
(pseudo-isocratic) for baseline resolution of the isomeric analytes (see Figure 35); 10–11 min, 
30% B, 11–12 min, 50% B; 12–13 min, 100% B; and 13–15 min 0% B. The flow rate was 0.5 
mL/min, and the injection volume was 5 µL. Table 12 shows the optimized run method 
conditions. 
2.7 UPLC-qTOF-MS: MS Settings 
Mass spectrometry was performed on a Waters Acquity UPLC equipped with a Waters Xevo 
G2-XS-qTOF-MS (Waters, Medford, MA). Data was acquired in sensitivity mode using positive 
electrospray ionization with a resolution > 20,000 at full width half maximum. The acquisition 
range was m/z 50–601 using a scan time of 0.1 s. Capillary voltage and cone voltage were 0.8 
kV and 20 V, respectively. The source temperature was 140°C, the desolvation gas flow rate was 
900 L/h at 250°C, and the cone gas flow rate was 50 L/h. Data acquisition used the MSE mode, 
with low collision energy (4 eV) and high-energy ramp (10–40 eV). Mass correction was 
performed during acquisition using an external reference (lockspray) composed of 2 µg/mL 
leucine enkephalin (monitoring m/z = 278.1114) solution infused at a flow rate of 5 µL/min. 
Table 12 shows the optimized method settings. 
 2.8 Data Processing  
The raw data obtained after analysis were processed by two types of software. Analyte 
identification criteria were manually assessed using Masslynx 4.1 software (Waters, Manchester, 
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UK); the raw data were also processed automatically using the streamlined workflow of the 
UNIFI 1.7.0 software (Waters, Manchester, UK) for identification and quantification of the 
analytes. Compound identification was based on retention time (±0.05 min), mass deviation (± 
10 mDa) and appropriate isotope profile. 
 
Figure 20: Schematic diagram of the analytical method used in this study 
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Table 12: Optimized UPLC-qTOF-MS method parameters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chromatography 
Liquid chromatography system: Waters ACQUITY UPLC 
Column: Waters ACQUITY® HSS T3 (2.1 x 100 mm, 1.8 μm) 
Column temperature: 45 °C 
Injection volume: 5 μL 
Solvent A: 
5 mM ammonium formate, adjusted to pH 2.9 using formic 
acid 
Solvent B: Acetonitrile containing 0.1% (v/v) formic acid 
Gradient: 
0 % solvent B (0-1 min) 
5 % solvent B (1-10 min) 
5-30 % solvent B (10-11 min) 
30-50 % solvent B (11-12min) 
50-100 % solvent B (12-13min) 
100-0 % solvent B (13-14 min) 
0 % solvent B (14-15 min) 
Flow rate: 0.5 mL/min 
  
Mass Spectrometry 
Mass spectrometer: Waters Xevo G2-XS QTof 
Ionizations mode: Electrospray +ve 
Capillary voltage: 800 V 
Cone voltage: 20 V 
Cone gas: 50 L/h 
Desolvation temperature: 250°C 
Desolvation gas: 900 L/h 
Source temperature: 140°C 
Data acquisition: MSE  centroid (data independent acquisition) 
Function 1: 4 eV 
Function 2: Ramp 10-40 eV 
Mass ange: 50 to 601 Da 
Resolution: > 20,000 @ 278 m/z (resolution mode) 
Lock Spray: leucine enkephalin = 278.1114 m/z 
Lock Spray Infused Rate: 5 µl/min 
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CHAPTER 3 
 
3. Analytical Interference in MIP-SPE / UPLC-qTOF-MS 
3.1 Introduction 
MIPs provide a medium with highly selective binding sites for analytes with specific 
structural features [174]. Accordingly, they have been promoted as highly selective SPE media 
for the extraction of target analytes and to minimize MEs while providing desirable reagent pH 
stability. However, the bleeding/leaching of residual template molecules from the polymer 
matrix is problematic with the advent of highly sensitive LC-MS detection schemes [175].  
We investigated this issue in the analysis of ARDs in aged blood by UPLC-qTOF-MS. EPH, a 
toxicologically important analyte, was observed to leach from a commercially available MIP 
template across numerous extracts of drug-free aged WB blood and aqueous matrices, increasing 
apparent instrument EPH response by more than 25% at an absolute EPH concentration of 20 
ng/mL. During the validation experiments, EPH interference were observed in the analysis of 
various aged, drug-free WB matrices. The method protocol was thoroughly investigated to 
identify the source of EPH observed 
3.2 MIP-SPE UPLC-qTOF-MS – Validation Experiments 
3.2.1 Evaluation of Matrix Effects (MEs) 
According to the SWGTOX standard practices for method validation in forensic toxicology, a 
study on MEs must include an evaluation of the matrix interference and ME (ionization 
suppression/enhancement) [176]. 
3.2.1.1 Evaluation of Matrix Interferences (MIs) 
MIs were evaluated to demonstrate the absence of common interferences from the WB 
matrix. Four different types of aged animal drug-free WB samples were pretreated and extracted 
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in triplicate by following the MIP pretreatment and extraction method explained in section 2.3 
(chapter 2). The extracted samples were then analyzed for the presence of any interferences. 
3.2.1.2 Evaluation of ME (Ionization Suppression/Enhancement) 
ME is analytically defined as the direct or indirect alteration or interference in the instrument 
response due to the presence of coeluting compounds [176]. Two different types of aged animal 
drug-free WB samples were pretreated and extracted in triplicate by following the MIP 
pretreatment and extraction method explained in Section 2.3. After extraction, the extracts were 
spiked and diluted to 20, 500, and 1000 ng/mL of the combined standard working solutions and 
IS solutions. Further, the spiked blood samples and the corresponding neat combined working 
standards were analyzed, and their instrumental responses were used to determine the magnitude 
of ME for each component by using the following equation: 
 
 
%ME = 
Response
spiked post-extracted sample
 
Response
standard (working)solution 
 x 100 
 
 
(2) 
 
where, 
ME < 100 indicates ion response suppression,  
ME > 100 indicates ion response enhancement. 
The acceptable range of ME is 100% ± 25% = 75%–125% 
 
3.2.2 Experimental Evaluation of EPH Interference 
WB samples (250 μL) from drug-free aged animal blood matrices, and aqueous samples (250 
μL) from drug-free aqueous solutions were extracted in triplicate by MIP-SPE, MMSPE, and 
FPTE by following the pretreatment and extraction methods described in chapter 2 (sections 2.3, 
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2.4, and 2.5, respectively). Extracts were then analyzed by the optimized UPLC-qTOF-MS 
method. Figure 21 shows the experimental design for the evaluation of EPH interference. 
 
Figure 21: Schematic diagram of the analytical method designed to evaluate ephedrine 
interference 
3.2 Results 
Data corresponding to the samples prepared by MIP-SPE and analyzed by the optimized 
UPLC-qTOF-MS method are summarized in Table 13 and shown in Figure 22. MIs and MEs 
were assessed as per the SWGTOX guidelines [176]. 
3.3.1 Matrix interferences  
Four different drug-free WB matrices were pretreated and extracted by MIP-SPE. The 
extracted samples were analyzed by the optimized UPLC-qTOF-MS method and their total ion 
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chromatograms (TICs) were checked for the presence of any interferences with respect to the 
retention time of the project analytes. An interferent was seen at the retention time of EPH in the 
total ion chromatogram (Figure 23). The extracted ion chromatogram (EIC) obtained by using 
the molecular ion of EPH (m/z 166) showed a peak at the same retention time as that of EPH 
(Figure 24). The mass spectrum of the interfering compound was obtained and compared with 
that of EPH (Figure 25). The interferent was identified as EPH after its retention time and mass 
spectrum profile matched those of EPH. 
3.3.2 Matrix Effects (Ionization Suppression/Enhancement) 
For EPH, measured ME values exceeded acceptable limits (≤ 25 %). Table 14 shows mean 
ME values for each analyte at three concentration levels (low, medium, and high) in aged bovine 
WB. Figure 26 graphically represents the mean ME values of analytes and internal standards at 
three concentration levels. Error bars represent the standard error of mean, whereas the two red 
lines represent the acceptable ME limits. EPH at a low concentration displayed an ME of 128% 
± 9%, which was above the acceptable limit of enhancement. Table 15 shows that EPH at a low 
concentration displayed an ME (131% ± 10%) beyond acceptable limits; sheep WB was used in 
this assay. Figure 27 graphically represents the mean ME values on analytes and internal 
standards at three concentration levels. The ME value of EPH at the low concentration level was 
131% ± 10%, which was above the acceptable limit of enhancement. 
3.3.3 Ephedrine (EPH) Interference 
3.3.3.1 Analysis of Drug-free Aged Animal Whole Blood 
EPH interference was seen in drug-free aged animal WB samples that were extracted by MIP-
SPE, but not by MMSPE or FPTE as observed in the TICs (Figure 28) and EIC (Figure 29). 
58 
 
Moreover, the mass spectrum of EPH matched with that of the interfering compound (Figure 30). 
The interfering compound was identified based on criteria shown in Table 16. 
3.3.3.2 Analysis of Drug-Free Aqueous Solution 
 EPH interference was also seen in drug-free aqueous samples that were extracted by MIP-
SPE, but not by MMSPE or FPTE. The EICs showed the presence of EPH interference at the 
retention time of that of EPH (Figure 31). Moreover, the mass spectrum of EPH matched with 
that of the interfering compound (Figure 32), and the compound was identified based on criteria 
as shown in Table 17. 
 
Table 13: Analyte Parameters under Optimized MIP-SPE and UPLC-qTOF-MS Conditions 
Drug 
Ionization  
Mode 
Molecular Ion  
(m/z) 
Fragmented Ion  
(m/z) (± 0.01) 
Retention Time  
(min) (± 0.05) 
Amphetamine−d11 Positive 147.1938 98.1078* / 130.1653 9.00 
Ephedrine−d3 Positive 169.1568 136.1195 / 151.1433* 7.54 
Norephedrine Positive 152.1180 115.0736 / 117.0736 / 134.0975* 5.36 
Cathine Positive 152.1180 115.0736 / 117.0736 / 134.0975* 6.05 
Ephedrine Positive 166.1378 115.0556 / 148.1208* / 149.1260 7.54 
Pseudoephedrine Positive 166.1378 115.0556 / 148.1208* / 149.1260 8.22 
Amphetamine Positive 136.1219 91.0553 / 119.0868* 9.31 
β-methylphenetylamine Positive 136.1219 91.0553 / 119.0868* 9.86 
*Quantifier Ions 
Selection of the quantifier and qualifier ions was based on transitions from the molecular ion to the most and second-most predominant 
fragment ions respectively, expect for the amphetamine and -methylphenethylamine the second most predominant fragmented ion was 
use as a quantifier ion (m/z 119 above m/z 100) to avoid any common putrefactive amine ion from the aged WB matrix, whereas the most 
predominant ion (m/z 91) was use as qualifier   
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Figure 22: Total ion chromatogram of a neat standard mixture of the amphetamine-related 
drugs (1000 ng/mL) and deuterated analogues (500 ng/mL). A; norephedrine, B; cathine, C; 
ephedrine, D; ephedrine-d3, E; pseudoephedrine, F; amphetamine-d11, G; amphetamine,                                       
H;-methylphenethylamine.  
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Figure 23: Total ion chromatogram of extract of drug-free bovine whole blood sample, extracted 
by molecular-imprinted polymer-solid phase extraction (A), and a 1 ng/mL neat standard 
mixture of ephedrine (1) and pseudoephedrine (2) (B). The red arrow indicates ephedrine 
interference observed in the total ion chromatograms of the drug-free bovine whole blood 
sample extracted by molecular imprinted polymer-solid phase extraction 
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Figure 24: Extracted ion chromatogram of the molecular ion of ephedrine (m/z 166) of a drug-
free bovine whole blood sample extracted by molecular imprinted polymer-solid phase 
extraction (A), and a 1 ng/mL neat standard mixture (B). 
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Figure 25: Mass spectrum of ephedrine in a drug-free bovine blood sample extracted by 
molecular imprinted polymer-solid phase extraction (A), and in a 1 ng/mL neat standard mixture 
(B). 
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 Table 14: Evaluation of matrix effects (%) of amphetamine-related drugs and deuterated 
analogues of aged bovine blood  
 
 
 
 
 
 
 
 
Analyte 
  Concentration    
 
Low  
20 ng/mL 
 
% CV 
Medium  
500 ng/mL 
% CV 
High  
1000 ng/mL 
% CV 
 
Amphetamine −d11 
99 ± 7 7.07 100 ± 6 6.00 109 ± 7 6.42 
 
Ephedrine−d𝟑 
 
102 ± 5 4.90 101 ± 1 0.99 106 ± 1 0.94 
 
Norephedrine 
 
102 ± 1 0.98 96 ± 1 1.04 97 ± 6 6.19 
 
Cathine 
 
103 ± 9 8.74 95 ± 1 1.05 93 ± 1 1.08 
 
Ephedrine 
 
128 ± 9 7.03 110 ± 3 2.73 105 ± 2 1.90 
 
Pseudoephedrine 
 
94 ± 2 2.13 104 ± 3 2.88 97 ± 6 6.19 
 
Amphetamine 
 
95 ± 8 8.42 95 ± 5 5.26 98 ± 3 3.06 
 
β-methylphenethylamine 
 
86 ± 4 4.65 92 ± 3 3.26 93 ± 2 2.15 
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Figure 26: Matrix effects (%) of amphetamine-related stimulants and two deuterated 
analogues at three different concentrations measured in extracted aged bovine whole blood. 
The data represent the mean of triplicate measurements; error bars represent the standard 
error of the mean and red lines represent the acceptable limits of matrix effects 
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Table 15: Evaluation of matrix effects (%) of amphetamine-related drugs and deuterated 
analogues of aged sheep blood 
 
 
 
 
 
 
 
 
Analyte 
  Concentration    
 
Low  
20 ng/mL 
 
% CV 
Medium  
500 ng/mL 
% CV 
High  
1000 ng/mL 
% CV 
 
Amphetamine−d11 
 
101 ± 2 1.98 100 ± 3 3.00 105 ± 4 3.81 
 
Ephedrine−d𝟑 101 ± 1 0.99 104 ± 9 8.65 100 ± 1 1.00 
 
Norephedrine 
 
104 ± 5 4.81 98 ± 4 4.08 97 ± 3 3.09 
 
Cathine 
 
104 ± 6 5.77 98 ± 5 5.10 97 ± 1 1.03 
 
Ephedrine 
 
131 ± 10 7.63 99 ± 4 4.04 98 ± 2 2.04 
 
Pseudoephedrine 
 
103 ± 2 1.94 101 ± 6 5.94 90 ± 6 6.67 
 
Amphetamine 
 
96 ± 1 1.04 99 ± 3 3.03 99 ± 2 2.02 
 
β -methylphenethylamine 
 
90 ± 2 2.22   87 ± 3 3.45 91± 1 1.10 
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Figure 27: Matrix effects (%) amphetamine-related drugs and two deuterated analogues at 
three different concentrations measured in extracted aged sheep whole blood. The data 
represent the mean of triplicate measurements; error bars represent the standard error of the 
mean and red lines represent the acceptable limits of matrix effects 
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Figure 28: Total ion chromatograms of drug-free bovine whole blood samples extracted by 
filtration pass-through extraction (A), mixed-mode solid phase extraction (B), molecular 
imprinted polymer-solid phase extraction (C), and a 1 ng/mL neat standard mixture of ephedrine 
and pseudoephedrine (D). The red arrow indicates ephedrine interference observed in the total 
ion chromatograms of the drug-free bovine blood sample extracted by molecular imprinted 
polymer-solid phase extraction 
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Figure 29: Extracted ion chromatograms of ephedrine by using the molecular ion m/z 166 of 
drug-free bovine whole blood samples extracted by filtration pass-through extraction (A), mixed-
mode solid phase extraction (B), molecular imprinted polymer-solid phase extraction (C), and in 
a 1 ng/mL neat standard mixture (D) 
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Figure 30: Mass spectra of ephedrine in drug-free bovine whole blood samples extracted by 
filtration pass-through extraction (A), mixed-mode solid phase extraction (B), molecular 
imprinted polymer-solid phase extraction (C), and in a 1 ng/mL neat standard mixture (D) 
1: TOF MS ES+ 
100 5.63e6 
 
 
 
 
 
 
 
 
 
 
0 
140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 
 
m/z 
1: TOF MS ES+ 
100 5.63e6 
 
 
 
 
 
 
 
 
 
 
 
0 
140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 
 
m/z 
1: TOF MS ES+ 
100 5.63e6 
 
 
 
 
 
 
 
166.1321 
 
148.1208 
0 
140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 
 
m/z 
100 
166.1321 
1: TOF MS ES+ 
5.63e6 
 
 
 
 
 
 
148.1208 
 
 
 
 
0 
140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 
 
m/z 
%
 
%
 
%
 
%
 
 
 
 
 
68 
 
Table 16: Experimental data on ephedrine interference in aged bovine blood 
SPE 
 
 
 
Sample 
No. 
 
 
 
Retention 
Time 
(min) 
Ion Instrumental Response 
Identified 
Analyte 166 
(m/z) 
S/N 
149 
(m/z) 
S/N 
148 
(m/z) 
S/N 
 
MMSPE 
 
 
 
1 
--- 0 0 0 0 0 0 ------- 
2 --- 0 0 0 0 0 0 ------- 
3 --- 0 0 0 0 0 0 ------- 
 
FPTE 
 
 
 
1 
--- 0 0 0 0 0 0 ------- 
2 --- 0 0 0 0 0 0 ------- 
3 --- 0 0 0 0 0 0 ------- 
 
MIP-SPE 
 
 
 
1 
7.56 16669 817 564 191 7171 616 Ephedrine 
2 7.56 15485 907 541 231 6584 466 Ephedrine 
3 7.56 17632 1120 630 177 7449 745 Ephedrine 
Mean 
 
 16595 948 578 200 7068 609  
STDEV 
 
 1075 155 46 28 441 139  
 
*S/N = signal to noise ratio; SPE, solid phase extraction; MM, mixed-mode; FPTE, filtration 
pass-through extraction; MIP, molecular imprinted polymer 
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Figure 31: Extracted ion chromatograms of ephedrine by using the molecular ion m/z 166 in 
aqueous solutions (mobile phase A) extracted by filtration pass-through extraction (A), mixed-
mode solid phase extraction (B), molecular imprinted polymer-solid phase extraction (C), and in 
a 1 ng/mL neat standard mixture (D). 
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Figure 32: Mass spectra of ephedrine in aqueous solutions extracted by filtration pass-through 
extraction (A), mixed-mode solid phase extraction (B), molecular imprinted polymer-solid phase 
extraction (C), and in a 1 ng/mL neat standard mixture (D)   
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Table 17: Experimental data on ephedrine interference in in aqueous solutions 
SPE 
 
 
 
Sample 
No. 
 
 
 
Retention 
Time 
(min) 
Ion Instrumental Response  
Identified 
Analyte 166 
(m/z) 
S/N 
149 
(m/z) 
S/N 
148 
(m/z) 
S/N 
 
MMSPE 
 
 
 
1 
--- 0 0 0 0 0 0 ------- 
2 --- 0 0 0 0 0 0 ------- 
3 --- 0 0 0 0 0 0 ------- 
 
FPTE 
 
 
 
1 
--- 0 0 0 0 0 0 ------- 
2 --- 0 0 0 0 0 0 ------- 
3 --- 0 0 0 0 0 0 ------- 
 
MIP-SPE 
 
 
 
1 
7.56 7573 416 294 70 3533 309 Ephedrine 
2 7.56 9180 412 262 72 3380 319 Ephedrine 
3 7.57 9960 468 388 74 3890 345 Ephedrine 
Mean 
 
 8904 432 314 72 3601 324  
STDEV 
 
 1075 155 46 28 441 139  
 
*S/N = signal to noise ratio; SPE, solid pahse extraction; MM, mixed-mode; FPTE, filtration 
pass-through extraction; MIP, molecular imprinted polymer 
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3.4 Discussion 
EPH, a toxicologically important analyte, was identified and observed to leach from a 
commercially available MIP across extracts of numerous drug-free aged animal WB and aqueous 
matrices (250 µL sample volume) in a phenomenon known as analyte bleeding. In such cases, 
template residues that are used to form the structure of the cavities in the polymeric particles are 
found to remain within the matrix of the designed polymer, despite extensive washing. This 
results in their leakage during sample extraction, and presence as a background interferent. This 
phenomenon can affect the detection accuracy of trace analytes, thereby significantly affecting 
forensic toxicological analysis [174, 176]. During validation, EPH interference was observed in 
the analysis of various drug-free aged animal WB matrices (Figures 22–24). To study the extent 
to which EPH interference affects the accuracy of the proposed analytical method, the ME of 
EPH was evaluated using two matrices of aged animal WB. It was observed that the apparent 
instrumental response for EPH at 20 ng/mL increased by more than 25% for both blood matrices. 
Due to the leaching of the template residue (EPH), ME crossed the acceptable levels at the low 
concentration level (20 ng/mL), but not at the medium (500 ng/mL), or high concentration level 
(1000 ng/mL) as shown in Table 14 and 15; these findings are graphically represented in Figure 
25 and 26. Upon further investigation, the source of EPH was traced to the MIP-SPE template. 
Consultation with the vendor revealed that EPH was used as a template in the synthesis of 
amphetamines-specific MIPs. Due to the combination of imperfect washing and the high 
sensitivity of the UPLC-qTOF-MS method used, residual template molecules leached out during 
sample extraction were detected and registered as a EPH interference. This was demonstrated 
through analysis of numerous matrices of aged animal WB and an aqueous solution (mobile 
phase A) were extracted by MIP-SPE, MMSPE, and FPTE. Interestingly, EPH was not detected 
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in WB or aqueous samples that were extracted by MMSPE or FPTE (Figures 28–32). The 
identity of the interferent as EPH was confirmed based on three fragment ions of EPH at m/z 
166, 149, and 148, their signal-to-noise ratios (S/Ns), and their retention times. The EIC, and 
mass spectrum of a neat standard of EPH matched with that of the interference compound in 
terms of the fragment ions formed and retention times. The S/Ns were above the lower 
acceptable limit (3:1) for all the three ions in the extracted aqueous and aged animal WB 
samples. 
3.5 Conclusion 
Although MIPs provide remarkable extraction selectivity, template leaching measurably 
interferes with the analysis of target analytes when instruments of very high sensitivity and 
selectivity are used; therefore, such an interference should be characterized and disclosed by all 
vendors. 
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Chapter 4 
4. Validation of a Method to Identify and Quantify Selected ARDs in WB 
using UPLC-qTOF-MS after Extraction by MMSPE 
4.1 Introduction 
ARDs are common compounds implicated in drug abuse in Saudi Arabia. This drug abuse 
plays an important role in early mortality due to traffic accidents, violence, and overdose. 
Consequently, the entire Saudi society has been affected from abusing ARDs. Therefore, control 
of ARDs abuse is important. In forensic toxicology, analysis of ARDs may be utilized to identify 
those driving or performing other tasks under the influence of drugs, to clarify the manner and 
cause of death, and to identify individuals who have been exposed to drugs in the recent past. For 
purposes of estimation of the degree of drug toxicity, this analysis is best carried out by using 
blood samples, since blood drug concentrations are generally best correlated with the extent of 
toxicity.  
Within the field of forensic toxicology, new analytical methods must undergo a process 
comprised of three stages prior to being adopted and incorporated within the laboratories’ 
standard analytical methods. The three stages involve development, validation, and verification. 
It is crucial in forensic toxicological analysis to obtain reliable, consistent, and accurate 
measurements. Therefore, validation of the developed method is a prerequisite to analyzing 
actual samples in forensic casework. Validation involves performing a set of experiments to 
estimate the efficacy and reliability of an analytical method [176]. In forensic toxicological 
analysis, these experiments must be performed according to the most recent professional 
standards for the intended application. One example of such standards are those established by 
SWGTOX [176]. 
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In this study, we report a validated analytical method to identify and quantify selected ARDs 
in WB using UPLC-qTOF-MS after extraction by MMSPE. The procedure requires 250 μL of 
WB to achieve a limit of quantification (LOQ) and detection (LOD) of 20 ng/mL for all analytes. 
Extraction recoveries of 63–90% and MEs of -21–9% were observed in aged animal WB 
samples. A quadratic polynomial equation was applied for fitting the calibration curves for all 
analytes. Satisfactory precisions below 20% and accuracies within 89–118% were obtained for all 
analytes. 
4.2 Method  
Method validation was done according to the standard practices established by SWGTOX 
[176]. 
4.2.1 Evaluation of Matrix Interferences (MIs): Selectivity 
MIs were evaluated to confirm the absence of substances that may interfere with analyte 
detection in WB matrices. Five different types of aged animal and human drug-free WB matrices 
were pretreated and extracted in triplicate by following the MMSPE pretreatment and extraction 
method explained in section 2.4 (chapter 2). These extracted samples were analyzed for MIs by 
UPLC-qTOF-MS. 
4.2.2 Evaluation of Matrix Effects (MEs): Ionization Suppression/Enhancement 
MEs are defined as the direct or indirect alteration or interference in the instrument response 
due to the presence of co-eluting compounds that comprise the sample matrix [176]. Five 
different types of aged animal and human drug-free WB matrices were pretreated and extracted 
in triplicate by following the MMSPE pretreatment and extraction method explained in section 
2.4 (chapter 2). The extracted drug-free samples were spiked with combined working standard 
and IS solutions in triplicate at concentrations of 20 (low), 500 (medium), 100 (high) ng/mL. 
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Spiked samples and corresponding neat standards were analyzed, and their instrumental 
responses were used to determine the magnitude of ME by using the following equation: 
 
 
%ME = 
Response
spiked post-extracted sample
 
Response
standard (working)solution 
 x 100 
 
 
(3) 
 
where, 
ME less than 100 indicates suppression, 
and ME greater than 100 indicates enhancement. 
The acceptable range of ME is considered as 100 ± 25 = 75–125 
 
MEs at each concentration level are represented as percentage increase or decrease in the peak 
areas of analytes in the samples relative to those of analytes in the neat standards. 
4.2.3 Evaluation of Recovery 
Recovery refers to the fraction of original analyte mass that is carried through the extraction 
process and is present in the final extract. It is measured as the ratio of analyte response in an 
extract to that of a drug-free extract after spiking the sample with the same mass of the analyte. 
Two different types of aged animal drug-free WB matrices were evaluated for recovery in 
triplicate at three concentration levels (low, medium, and high) in pre- and post-extraction spiked 
samples. Both samples were processed by following the MMSPE pretreatment and extraction 
method explained in section 2.4 (chapter 2). The samples were spiked with combined working 
standard and IS solutions in triplicate at concentrations of 20 (low), 500 (medium), and 1000 
(high) ng/mL either before (pre-extraction spiked) or after (post-extraction spiked) extraction. 
The spiked samples were analyzed, and their instrumental responses were used to determine the 
magnitude of recovery by using the following equation: 
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 %RE = (
Response
pre-extraction spiked sample
 
Response
post-extraction spiked sample
 ) × 100 
 
 
(4) 
 
4.2.4 Evaluation of Carryover 
Carryover was evaluated by analyzing extracts of 250 μL of drug-free WB (n = 3) after 
analyzing a high-concentration calibrator (1000 ng/mL, n = 3) of the analytes. Both the samples 
were pretreated and extracted by the MMSPE extraction method described in section 2.4. 
4.2.5 Evaluation of Calibration 
Calibrators (250 µL) were prepared in drug-free aged bovine WB matrix at concentrations of 
20, 40, 200, 500, 800, 1000 ng/mL by using combined working standard solutions each 
containing 125 ng of ISs (section 2.2). All samples were pretreated and extracted by the MMSPE 
extraction method (section 2.4) and analyzed by UPLC-qTOF-MS (sections 2.6, 2.7, and 2.8). 
Quantification was performed by measurement of the ratio of peak areas of the analytes relative 
to those of the corresponding deuterated analogs in the specific EICs; deuterated AMP was used 
for quantifying AMP and BMP, and deuterated EPH was used for quantifying EPH, PEPH, 
NEPH, and CAT. Calibration curves were constructed and assessed using quadratic regression 
(considered acceptable if R2 ≥ 0.99) of peak area ratios versus concentration on each of five 
different days. Each calibration curve was constructed using six calibrators in triplicate for each 
analyte. Furthermore, a batch of blind samples were analyzed in triplicate at two concentration 
levels along with the calibrators for purposes of assessment of analytical bias. 
The working concentration range of the method was 20–1000 ng/mL for all analytes. The 
LOD was administratively defined as 20 ng/mL by using the lowest non-zero calibrator method 
(the calibrator with lowest concentration assayed with response that met precision criteria), due to 
the lack of toxicological significance of the analyte compounds at blood concentrations below 20 
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ng/mL. Fifteen samples with analytes at a concentration of 20 ng/mL were used to identify the 
LOD. All these samples were pretreated and extracted by following the MMSPE method (section 
2.4). Similarly, the LOQ was also identified by following the same method for identifying LOD.  
Analytical precision was measured as the coefficient of variation (%CV) of triplicate 
measurements at the assayed concentration range on each of five different days. It was considered 
acceptable when the %CV was  20%. Bias was determined after blinded analysis of triplicate 
samples at two different concentrations of each analyte per run. Bias was considered acceptable 
when the measured concentration was within 20% of the theoretical concentration. 
4.2.6  Evaluation of Autosampler Stability 
Analyte stability within the autosampler (maintained at 10°C) of the UPLC-qTOF-MS was 
evaluated by repeated injection of extracted samples at three different concentration levels (40, 
500, and 1000 ng/mL; n = 3) after 0, 12, 24, and 36 h. Analytes were considered stable if the 
deviation in analyte response was within 20% of the response of the corresponding sample at t= 0 
h 
4.3 Results 
UPLC-qTOF-MS data for samples prepared by MMSPE are summarized in Table 18 and 
shown in Figure 33.  
4.3.1 Matrix Interferences (Selectivity and Specificity)  
No MI was observed in the EICs at the retention times of the analytes in the five-different 
aged animal and human WB matrices (Table 19). 
4.3.2 Matrix Effects (Ionization Suppression/Enhancement)  
MEs (suppression/enhancement) were < 25 % for all analytes in the five different WB 
matrices assayed. Tables 20–24 show the ME values of all analytes in aged bovine, sheep, and 
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human WB matrices, respectively; Figures 34–38 graphically represent the respective mean ME 
values. 
4.3.3 Recovery  
Recovery ranged from 60–90% for all analytes in aged bovine (Table 25 and Figure 39) and 
sheep (Table 26 and Figure 40) WB matrices. 
4.3.4 Carryover  
Carryover was evaluated by analysis of three drug-free aged animal WB extracts directly after 
analyzing the high concentration calibrator (1,000 ng/mL, n = 3) samples. No carryover was 
observed upon visual inspection of the chromatograms and after the analysis of EICs. 
4.3.5 Calibration of Analytical Response 
Analytical response ratios were fit to calibrator concentrations using quadratic regression 
equations over a range of 20–1,000 ng/mL. Strong correlations (R2 > 0.99) were observed on all 
five days. Table 27 shows the averaged calibration curve regression equations and correlation 
coefficients for all analytes. Averaged quadratic calibration curves are shown in Figures 41 
(NEPH and CAT), 42 (EPH and PEPH), and 43 (AMP and BMP). The LOD and LOQ were 
determined to be 20 ng/mL for all analytes. Intra- and inter-day precision were 1.00–18.30% and 
6.60–19.70%, respectively; they were deemed acceptable. The accuracy of the method was also 
acceptable (-11–18.25%). Table 28 summarizes the parameters determining analytical 
performance. 
4.3.6 Stability of Analytes in Autosampler 
The stability of the analytes in the autosampler was assessed at three different concentrations 
over 36 h. For all analytes, there was no change in response ratio in excess of 20% of the initial 
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response (t = 0 h), indicating that they remained stable while on the instrument waiting to be 
injected (Table 29). 
 
Table 18: Analytical parameters of the analytes 
Drug 
Ionisation Mode 
Molecular Ion 
(m/z) 
Fragmented Ion (m/z) 
(± 0.01) 
Retention Time 
(min) 
(± 0.05) 
     
Amphetamine−d11 Positive 147.1938 98.1078* /130.1653 8.76 
Ephedrine−d3 Positive 169.1568 136.1195 /151.1433* 7.30 
Norephedrine Positive 152.1180 115.0736 / 117.0736 /134.0975* 5.21 
Cathine Positive 152.1180 115.0736 / 117.0736 /134.0975* 5.90 
Ephedrine Positive 166.1378 115.0556 / 117.0713 / 148.1140* / 149.1160 7.31 
Pseudoephedrine Positive 166.1378 115.0556 / 117.0713 / 148.1140* / 149.1160 8.00 
Amphetamine Positive 136.1219 91.0553 / 119.0868* 9.05 
β-methylphenethylamine Positive 136.1219 91.0553 / 119.0868* 9.58 
     
*Quantifier ions 
 
 
 
Table 19: Evaluation of matrix interferences in five drug-free whole blood matrices after 
extraction. 
Number Whole Blood Matrix Result 
   
1 Bovine  No interference 
2 Sheep  No interference 
3 Human Sample 1 No interference 
4 Human Sample 2 No interference 
5 Human Sample 3  No interference 
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Figure 33: Total ion chromatogram of extracted aged animal whole blood; (A) drug-free 
control, and (B) spiked with 800 ng/mL of the combined working solution and 500 ng/mL of the 
internal standard solution; (1) norephedrine, (2) cathine, (3) ephedrine-d3, (4) ephedrine, (5) 
pseudoephedrine, (6) amphetamine-d11,(7) amphetamine, and (8) -methylphenethylamine 
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Table 20: Evaluation of matrix effects (%) of aged bovine whole blood on amphetamine-related 
drugs and deuterated analogues 
Figure 34: Matrix effects (%) measured in extracts of aged bovine whole blood spiked with 
amphetamine-related drugs, including two deuterated analogues, at three different concentration 
levels (20, 500 and 1000 ng/mL). The data shown represent the mean of triplicate analysis, error 
bars represent the standard error of mean, and red lines represent acceptable limits of matrix 
effects.  
Analyte 
  Concentration    
 
Low  
20 ng/mL 
 
% CV 
Medium  
500 ng/mL 
% CV 
High  
1000 ng/mL 
% CV 
 
Amphetamine−d11 
 
84 ± 3 3.57 87 ± 3 3.45 89 ± 1 1.12 
 
Ephedrine−d𝟑 
 
87 ± 5 5.75 88 ± 3 3.41 86 ± 6 6.98 
 
Norephedrine 
 
89 ± 3 3.37 90 ± 2 2.22 87 ± 1 1.15 
 
Cathine 
 
87 ± 3 3.45 91 ± 2 2.20 87 ± 2 2.30 
 
Ephedrine 
 
88 ± 10 11.36 86 ± 4 4.65 87 ± 7 8.05 
 
Pseudoephedrine 
 
86 ± 6 6.98 91 ± 2 2.20 91 ± 2 2.20 
 
Amphetamine 
 
93 ± 2 2.15 94 ± 2 2.13 92 ± 2 2.17 
β-methylphenethylamine 
 
93 ± 4 4.26 94 ± 1 1.06 91 ± 4 4.40 
0
25
50
75
100
125
Amphetamine-d11 Ephedrine-d3 Norephedrine Cathine Ephedrine Pseudoephedrine Amphetamine β-methylphenethylamine 
M
a
t
r
i
x
 
E
f
f
e
c
t
 
M
e
a
n
 
(
%
)
 
Analytes
20 ng/mL
500 ng/mL
1000 ng/mL
83 
 
Table 21: Evaluation of matrix effects (%) of aged sheep whole blood on amphetamine-related 
drugs and deuterated analogues 
Figure 35: Matrix effects (%) measured in extracts of aged sheep whole blood spiked with 
amphetamine-related drugs, including two deuterated analogues, at three different 
concentrations (20, 500 and 1000 ng/mL). The data represent the mean of triplicate analysis, 
error bars represent the standard error of mean, and red lines represent acceptable limits of 
matrix effects. 
Analyte 
Concentration 
 
Low 
20 ng/mL 
 
% CV 
Medium 
500 ng/mL 
% CV 
High 
1000 ng/mL 
% CV 
 
Amphetamine−d11 
 
101 ± 8 7.92 101 ± 1 0.99 100 ± 1 1.00 
 
Ephedrine−d𝟑 
 
96 ± 9 9.38 106 ± 2 1.89 95 ± 4 4.21 
 
Norephedrine 
 
98 ± 3 3.06 100 ± 2 2.00 95 ± 1 1.05 
 
Cathine 
 
96 ± 1 1.04 99 ± 2 2.02 94 ± 1 1.06 
 
Ephedrine 
 
109 ± 5 4.59 98 ± 3 3.06 98 ± 1 1.02 
 
Pseudoephedrine 
 
109 ± 3 2.75 104 ± 1 0.96 95 ± 2 2.11 
 
Amphetamine 
 
101 ± 6 5.94 100 ± 2 2.00 99 ± 2 2.02 
β-methylphenethylamine 
 
102 ± 7 6.86 99 ± 1 1.01 99 ± 3 3.03 
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Table 22: Evaluation of matrix effects (%) of human whole blood (Source 1) on amphetamine-
related drugs and deuterated analogues 
Figure 36: Matrix effects (%) measured in extract of human whole blood (Source 1) spiked with 
amphetamine-related drugs, including two deuterated analogues, at three different 
concentrations (20, 500 and 1000 ng/mL). The data represent the mean of triplicate analysis, 
error bars represent the standard error of mean, and red lines represent acceptable limits of 
matrix effects. 
 
Analyte 
Concentration 
 
Low 
20 ng/mL 
 
% CV 
Medium 
500 ng/mL 
% CV 
High 
1000 ng/mL 
% CV 
 
Amphetamine−d11 
 
87 ± 3.0 3.45 81 ± 2.7 3.33 85 ± 4.4 5.18 
 
Ephedrine−d𝟑 
 
89 ± 3.3 3.71 81 ± 2.4 2.96 83 ± 3.0 3.61 
 
Norephedrine 
 
83 ± 4.5 5.42 80 ± 1.0 1.25 82 ± 2.9 3.54 
 
Cathine 
 
86 ± 2.2 2.56 81 ± 2.5 3.09 82 ± 2.2 2.68 
 
Ephedrine 
 
87 ± 3.2 3.68 81 ± 2.2 2.72 79 ± 1.0 1.27 
 
Pseudoephedrine 
 
89 ± 1.9 2.13 82 ± 1.1 1.34 81 ± 1.0 1.23 
 
Amphetamine 
 
88± 5.2 5.91 83 ± 1.2 1.45 85 ± 1.0 1.18 
β-methylphenethylamine 93 ± 4.7 5.05 86 ± 1.0 1.16 86 ± 0.2 0.23 
0
25
50
75
100
125
Amphetamine-d11 Ephedrine-d3 Norephedrine Cathine Ephedrine Pseudoephedrine Amphetamine β-methylphenethylamine
M
a
t
r
i
x
 
E
f
f
e
c
t
 
M
e
a
n
 
(
%
)
 
Analytes
20 ng/mL
500 ng/mL
1000 ng/mL
85 
 
Table 23: Evaluation of matrix effects of human whole blood (Source 2) on amphetamine-related 
drugs and deuterated analogues 
 
Figure 37: Matrix effects (%) measured in extract of human blood (Source 2) spiked with 
amphetamine-related drugs, including two deuterated analogues, at three different 
concentrations (20, 500 and 1000 ng/mL). The data represent the mean of triplicate analysis, 
error bars represent the standard error of mean, and red lines represent acceptable limits of 
matrix effects. 
Analyte 
Concentration 
 
Low 
20 ng/mL 
 
% CV 
Medium 
500 ng/mL 
% CV 
High 
1000 ng/mL 
% CV 
 
Amphetamine−d11 
 
87 ± 4 4.60 89 ± 4 4.49 88 ± 2 2.27 
 
Ephedrine−d𝟑 
 
93 ± 6 6.45 89 ± 6 6.74 87 ± 3 3.45 
 
Norephedrine 
 
91 ± 2 2.20 92 ± 4 4.35 91 ± 2 2.20 
 
Cathine 
 
88 ± 2 2.27 91± 1 1.10 91 ± 1 1.10 
 
Ephedrine 
 
91 ± 2 2.20 89 ± 5 4.49 88± 2 2.27 
 
Pseudoephedrine 
 
89 ± 2 2.25 90 ± 4 4.44 89 ± 2 2.25 
 
Amphetamine 
 
84± 3 3.57 91 ± 1 1.10 98 ± 3 3.06 
β-methylphenethylamine 85 ± 4 4.71 94 ± 2 2.13 99 ± 0.1 0.10 
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Table 24: Evaluation of matrix effects of human whole blood (Source 3) on amphetamine-related 
drugs and deuterated analogues 
Figure 38: Matrix effects (%) measured in extract of human blood (source 3) spiked with  
amphetamine-related drugs, including two deuterated analogues, at three different 
concentrations. The data represent the mean of triplicate analysis, error bars represent the 
standard error of mean, and red lines represent acceptable limits of matrix effects. 
Analyte 
Concentration 
 
Low 
20 ng/mL 
 
% CV 
Medium 
500 ng/mL 
% CV 
High 
1000 ng/mL 
% CV 
 
Amphetamine−d11 
 
82 ± 1 1.22 89 ± 2 2.25 90 ± 1 1.11 
 
Ephedrine−d𝟑 
 
84 ± 4 4.76 89 ± 1 1.12 92 ± 2 2.17 
 
Norephedrine 
 
83 ± 5 6.02 92 ± 2 2.17 95 ± 1 1.05 
 
Cathine 
 
82 ± 3 3.66 93± 3 3.23 96 ± 4 4.17 
 
Ephedrine 
 
84 ± 2 2.38 90 ± 1 1.11 91± 2 2.20 
 
Pseudoephedrine 
 
83 ± 2 2.41 90 ± 2 2.22 93 ± 3 3.23 
 
Amphetamine 
 
83± 2 2.41 97 ± 4 4.12 101 ± 2 1.98 
β-methylphenethylamine 89 ± 4 4.49 97 ± 4 4.12 101 ± 0.2 0.20 
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Table 25: Evaluation of recovery (%) of amphetamine-related drugs and deuterated analogues 
from aged bovine whole blood 
 
Figure 39: Recovery (%) of amphetamine-related drugs, including two deuterated analogues at 
three different concentrations from extract of spiked aged bovine whole blood. The data 
represent the mean of triplicate analysis, and error bars represent the standard error of mean. 
Analyte 
Concentration 
 
Low 
20 ng/mL 
 
% CV 
Medium 
500 ng/mL 
% CV 
High 
1000 ng/mL 
% CV 
 
Amphetamine−d11 
 
70 ± 3 4.29 70 ± 1 1.43 71 ± 2 2.82 
 
Ephedrine−d𝟑 
 
77 ± 4 5.19 77 ± 1 1.30 77 ± 4 5.19 
 
Norephedrine 
 
71 ± 3 4.23 72 ± 2 2.78 76 ± 1 1.32 
 
Cathine 
 
68 ± 3 4.41 71 ± 2 2.82 77 ± 1 1.30 
 
Ephedrine 
 
71 ± 4 5.63 75 ± 1 1.33 77 ± 7 9.09 
 
Pseudoephedrine 
 
68 ± 3 4.41 75 ± 4 5.33 90 ± 5 5.56 
 
Amphetamine 
 
70 ± 3 4.29 80 ± 1 1.25 80 ± 2 2.50 
β-methylphenethylamine 65 ± 4 6.15 73 ± 1 1.37 75 ± 1 1.33 
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Table 26: Evaluation of recovery (%) of amphetamine-related drugs and deuterated analogues 
from aged sheep whole blood 
Figure 40: Recovery (%) of amphetamine-related drugs, including two deuterated analogues, at 
three different concentrations from extract of spiked aged sheep whole blood. The data represent 
the mean of triplicate analysis, and error bars represent the standard error of mean. 
Analyte 
Concentration 
 
Low 
20 ng/mL 
 
% CV 
Medium 
500 ng/mL 
% CV 
High 
1000 ng/mL 
% CV 
 
Amphetamine−d11 
 
60 ± 7 11.67 62 ± 7 11.29 61 ± 6 9.84 
 
Ephedrine−d𝟑 
 
70 ± 12 17.14 77 ± 4 5.19 90 ± 6 6.67 
 
Norephedrine 
 
70 ± 5 7.14 70 ± 5 7.14 81 ± 8 9.88 
 
Cathine 
 
67 ± 7 10.45 67 ± 4 5.97 79 ± 7 8.86 
 
Ephedrine 
 
65 ± 5 7.69 67 ± 5 7.46 70 ± 1 1.43 
 
Pseudoephedrine 
 
63 ± 2 3.17 68 ± 2 2.94 87 ± 1 1.15 
 
Amphetamine 
 
69 ± 3 4.35 72 ± 6 8.33 74 ± 4 5.41 
β-methylphenethylamine 60 ± 2 3.33 68 ± 6 8.82 70 ± 6 8.57 
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Table 27: Averaged curve regression equations and correlation coefficients of the analytes in 
aged bovine whole blood 
 
 
 
Figure 41: Averaged quadratic calibration curves of norephedrine and cathine 
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Figure 42: Averaged quadratic calibration curves of ephedrine and pseudoephedrine 
 
 
Figure 43: Averaged quadratic calibration curves of amphetamine and -methylphenylamine.  
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Table 28: Summary of analytical performance parameters 
Analyses were performed using five different sets of extractions of analyte standard mixtures ranging from 20 to 
1,000 ng/mL over six non-zero calibration points; each standard concentration was analyzed in triplicate. LOD, 
limit of detection; LOQ, limit of quantitation 
 
Table 29: Analyte stability data for amphetamine-related drugs at three different concentrations while 
resident on autosampler (10 ºC) over 36 h. 
 
Drug Limit of detection 
(LOD, ng/mL) 
Limit of 
quantitation 
(LOQ, ng/mL) 
Within-Run Precision  
(CV, %)  
(acceptance criteria: ≤20%) 
 [# failed] 
Between-Run Precision  
(CV, %)  
(acceptance criteria: ≤20%)  
[# failed] 
Bias (%)  
(acceptance criteria: 
≤20%) [# failed] 
      
Norephedrine 20 20 1.17–18.10 [0/90] 15.86–18.99 [0/30] -4.72-18.25 [0/10] 
Cathine 20 20 1.60–13.20 [0/90] 16.2–18.98 [0/30] -5.00-15.00 [0/10] 
Ephedrine 20 20 1.00–11.54 [0/90] 5.31–9.81 [0/30] -6.90-8.40 [0/10] 
Pseudoephedrine 20 20 1.06–12.01 [0/90] 3.50–9.38 [0/30] -10.82-7.16 [0/10] 
Amphetamine 20 20 1.00–18.3 [0/90] 7.95–19.70 [0/30] -7.98-3.40 [0/10] 
       β-methylphenethylamine 20 20 1.50–15.78 [0/90] 6.60–18.95 [0/30] -11.00-9.00 [0/10] 
      
Drug 
 
(CV, %) (acceptance criteria: ≤20%) 
 
40 ng/mL 500 ng/mL 1000 ng/mL 
  12 hours     24 hours   36 hours   12 hours    24 hours   36 hours 0 12 hours   24 hours   36 hours 
Norephedrine 5.32 5.32 5.32 1.62 1.35 1.83 2.63 2.63 2.38 
Cathine 5.42 1.76 2.34 2.6 4.62 2.22 2.39 1.29 1.16 
Ephedrine 2.24 2.37 6.04 1.39 1.07 1.12 1.36 3.35 3.48 
Pseudoephedrine 1.56 2.57 2.94 0.57 0.98 1.2 4.22 7.26 7.77 
Amphetamine 0.32 0.32 0.32 2.98 2.62 5.45 1.51 3.24 4.17 
  β-methylphenethylamine 0.30 0.18 0.92 2.81 2.77 5.89 2.46 4.2 4.81 
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4.4 Discussion 
This study was conducted to develop and validate a qualitative and quantitative method to 
determine ARDs in WB by UPLC-qTOF-MS after extracting the samples by MMSPE. 
Validation of the analytical method was based on standards established by SWGTOX [176]. To 
optimize the extraction process, several experiments were performed, including the evaluation of 
different precipitation agents, modes of SPE, and conditions of UPLC-qTOF-MS analysis. 
Samples of WB were precipitated using MeOH and ACN, alone or in combination. Based on 
visual inspection of the supernatant (i.e., clarity), ACN was deemed to be the most suitable 
precipitation agent in the pretreatment step of WB samples. After evaluating two types of SPE 
platforms for the extraction step (chapter 2), MMSPE was found to be superior to MIP-SPE 
because it did not elicit any interference to response associated with key analytes (chapter 3). 
The six selected ARDs included two pairs of diastereomers (NEPH and CAT, and EPH and 
PEPH) and one pair of positional isomers (AMP and BMP). Therefore, fragmentation patterns 
for each pair of isomers were expected to be very similar or indistinguishable. To overcome this 
analytical challenge, chromatographic resolution of the ARDs was crucial. Accordingly, a 
pseudo-isocratic elution method was developed in which the composition of the UPLC mobile 
phase was varied at very shallow gradients (from 0% B to 5% B over 9 min) to facilitate the 
complete baseline resolution of the isomeric analytes (Figure 33 and Tables 12, 18). 
Rapid, alternating acquisition of MS spectra at low (LE) and high (HE) collision energies 
during qTOF-MS analysis was performed in the MSE mode. Ions from intact molecules were 
generally and predominantly detected at LE, whereas more extensive fragmentation data was 
acquired at HE. In a single injection, this technique enables the acquisition of ions from 
precursor molecules and their fragment ions [177]. Low capillary voltage (0.8 kV) facilitated the 
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detection of low-molecular-mass ARDs (135–168 Da) with optimum sensitivity. Similarly, the 
cone voltage was also set to a low voltage (20 V) as shown in Table 12. The analytical method 
was optimized for these parameters (Table 18).  
Both isomer pairs, NEPH and CAT, and EPH and PEPH, formed [M+H]
+
 ions with m/z 152 
and 166, respectively. Consequently, by losing water from their molecular ions [M+H-H2O]
+
, 
the isomer pairs formed fragments with m/z 134 and 148, respectively. NEPH and CAT also 
yielded [M+H-H2O-NH2]
+
 with m/z 117 after subsequently losing ammonia, whereas EPH and 
PEPH yielded [M+H-H2O-NH-CH3]
+
 with m/z 117 after losing methylamine. Moreover, [M+H-
H2O-NH2-H2
+
 with m/z 115 was formed by both isomer pairs due to the loss of H2 [178]. 
Ephedrine-d3 yielded [M+H]
+
, [M+H-H2O]
+
, and [M+H-H2O-CH3]
+ 
with m/z 169, 151, and 136, 
respectively [178]. AMP and BMP displayed the same fragmentation pattern. They formed 
[M+H]
+
 with m/z 136. Subsequently, they formed [M+H-NH2]
+
 with m/z 119 by losing 
ammonia and tropylium ion [M+H-NH2-CH3-CH]
+
 with m/z 91 as a result of a β-C-C cleavage. 
Amphetamine-d11 formed [M+H]
+
, [M+H-NH2]
+
, and [M+H-NH2-CD3-CD]
+ 
with m/z 147, 130, 
and 98, respectively (see appendix A).  
The developed method was validated by evaluating MIs, MEs, recovery, carryover, 
autosampler stability, and calibration to measure bias, intra- and inter-day accuracy, and 
precision. Five types of drug-free WB matrices (Table 19) were extracted and analyzed without 
the addition of ISs. Each sample was analyzed to confirm the absence of MIs by monitoring the 
quantifier and qualifier ions of the analytes of interest at their respective retention times; no MI 
was detected in the five WB matrices. 
Changes (enhancement or suppression) of analyte responses due to matrix effects (MEs) must 
be less than 25%as per SWGTOX guidelines. MEs of the five different WB matrices on the 
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responses of all analytes at all concentration levels assayed were less than 25% (with %CV ≤ 
20%). The majority of the ME values were negative for bovine, and human source 1, 2, and 3 
WB matrices, indicating ion suppression as shown in Tables 20, 22, 23, and 24, respectively. 
However, ion enhancement was observed in the sheep WB matrix as shown by positive ME 
values (Table 21). Recovery was evaluated using aged bovine and sheep WB matrices; it was 
65–90% for all analytes extracted from bovine WB (Table 25), whereas it was 60–90% for all 
analytes extracted from sheep WB (Table 26) at all concentration levels (with %CV ≤ 20%). 
Low recovery values, especially at low analyte concentrations, were observed. These low 
recovery values might be due to the loss of analytes because of the polarity and volatility of 
ARDs. The deactivation of any utilized glass apparatus during the extraction and preventing the 
protonated amine group of ARDs from interacting with the hydroxyl group of glass silicone 
could increase analyte recovery and reduce ME. This remedial step was not incorporated in this 
study due the high cost of silanized glass tubes. Therefore, further experiments are required to 
verify its benefits. 
Analyte carryover may compromise the accuracy of qualitative or quantitative analysis. ARDs 
were evaluated for carryover by analyzing drug-free WB extracts immediately following the 
analysis of the corresponding upper calibrator (1000 ng/mL) in triplicate. None of the analytes in 
this study displayed carryover effects. 
Accuracy and precision were determined by constructing calibration curves for each analyte 
on each of five separate days and running two blind samples (one high (640-960 ng/mL) and one 
low (32-48 ng/mL unknown concentration samples) with each curve. The curves were produced 
using calibrators prepared in triplicate at 20, 40, 200, 500, 800, and 1000 ng/mL. The LOQ was 
determined to be the lowest point on the curve that demonstrated a precision of ≤ 20% and an 
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S/N ratio ≥ 10. The LOD was determined to be equal to the LOQ as the lowest concentration that 
was measured on the curve (the lowest non-zero calibrator method). R2 values (0.999–1) that 
were observed for each curve showed a good fit; each curve was fit with a quadratic regression 
equation. Table 27 shows the averaged regression equations and correlation coefficients of five 
curves for the analytes in aged bovine WB. Figures 41, 42, and 43 show the averaged quadratic 
calibration curves of NEPH and CAT, EPH and PEPH, and AMP and BMP, respectively. 
The concentration of each unknown blind sample was calculated using the equation of the line 
of best fit, and bias was determined by comparing the calculated and theoretical concentrations 
by using the following equation: 
  
 Bias (%) at Concentrationx= [
 Grand Mean of Calculated Concentrationx-Theoretical Concentrationx 
Theoretical Concentrationx
]  × 100 
 
(5) 
 
Bias values up to 20% are permissible as per SWGTOX guidelines [176]. The high and low 
concentration blind samples for all analytes exhibited acceptable bias values, indicating that the 
method is reliable at both the high and low ends of the curve. Bias results of 10 blind and 
calibrator samples analyzed on five separate days are shown for each analyte in Table 28. 
Precision, expressed as %CV, is the closeness of agreement between a series of measurements 
obtained from multiple samples of the same homogenous sample population [176]. Imprecision 
can lead to inaccurate quantitative results. SWGTOX guidelines state that the %CV shall not 
exceed 20% at any concentration level. Intra- and inter-run precisions were calculated. Intra-run 
precision was calculated using the values obtained in each run after triplicate analyses at each 
concentration as follows: 
 
 
 Intra-run %CV= [
 Standard deviation of a single run of samples 
 Mean calculated value of a single run of samples 
]  × 100 
 
(6) 
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Inter-run precision was calculated using the values obtained in each run after triplicate analyses 
at each concentration as follows: 
 
 
Inter-run %CV= [
 Standard deviation of the grand mean for each concentration 
 Grand mean for each concentration
]  × 100 
 
(7) 
 
The %CV for all analytes at all six concentrations were within the acceptable precision limit 
(≤ 20%). Table 28 presents the results of the accuracy and precision of the assay. 
The stability of each analyte while samples resided in the autosampler was assessed. Stability 
is defined as the ability of an analyte to resist chemical change in a matrix under specific 
conditions for given time intervals [176]. It is a measure of the time for which an analyte can 
remain under those conditions before the interpretation of its concentration is affected; a change 
in response beyond ± 20% from the initial response indicates a loss of analyte stability. The 
relative change in response was measured at three concentrations (40, 500, and 1000 ng/mL) in 
triplicate at 0, 12, 24, and 36 h. The samples were maintained in the autosampler at 10°C. All 
analytes were stable throughout the period of evaluation as shown in Table 29, indicating that 
ARDs can reliably be quantified for at least 36 h under the autosampler conditions used here. 
4.5 Conclusion  
This work involved development and validation of a method for quantitative analysis of 
selected ARDs by UPLC-qTOF-MS in WB after extraction by MMSPE. The method was 
validated according to the standard practices of SWGTOX. The validation experiments 
demonstrated that the assay has acceptable accuracy and precision for use in forensic toxicology. 
Additionally, the study demonstrated the utility of UPLC-qTOF-MS for the qualitative and 
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quantitative determination of ARDs in WB. Consequently, it holds potential for screening and 
quantification studies in forensic toxicology. 
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Chapter 5 
 
5.0    Determination of -methylphenethylamine and Its Metabolites in Whole 
Blood of Rats Using MMSPE and UPLC-qTOF-MS 
 
5.1    Introduction 
BMP is a recreational drug that was synthesized in the 1930s as an alternative analog of AMP 
[95, 96]; it is a positional isomer of AMP. Figure 24 shows the chemical structures of AMP and 
BMP [96]. Pharmacologically, BMP acts as a DA-receptor agonist, facilitating DA release and 
inhibiting DA reuptake from the synaptic cleft, but to a lesser extent than AMP does. The 
metabolism of BMP is poorly understood, and the efficacy and safety of BMP have never been 
evaluated in humans. Hence, its use as an ingredient in weight loss products and dietary 
supplements has been banned by the FDA [96]. To our knowledge, no pharmacokinetic study of 
BMP has been performed in animals. Therefore, one of the main goals of this project was to 
partially investigate the metabolic pathway of BMP in rats.  
In this study, the validated analytical assay described in Chapter 4 for the identification and 
quantification of selected ARDs in WB by MMSPE and UPLC-qTOF-MS was used to determine 
BMP concentrations and to identify any of its metabolites in cardiac WB from rats exposed to 
BMP. There was one newly detected metabolite of BMP, which is proposed to be 1-amino-2-
phenylpropan-2-ol. This proposed metabolite structure was determined through its fragmentation 
pattern by using the MSE acquisition mode of qTOF-MS. Further experiments are required to 
confirm the proposed chemical structure of this newly detected metabolite of BMP.  
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5.2    Method 
5.2.1    Drug Administration to Rats and Blood Sampling 
Male Sprague-Dawley rats (230–250 g, n = 12) were provided by Charles River Laboratories 
(St-Constant, QC, Canada). The animals were housed in an environmentally controlled breeding 
room at the Laurentian University Animal Care Facility and were acclimated to the laboratory 
conditions for 3 days. Adult male Sprague-Dawley rats were housed in groups of three in cages 
with ¼″ bedding (Harlan Teklad, Indianapolis, IN, USA) under a 12-h light/dark cycle at a 
temperature of 20 ºC. The animals were provided free access to water and Harlan Teklad 
laboratory diet 8640. The animal procedures used in this study were approved by the Laurentian 
University Animal Care Committee. Twelve adult male Sprague-Dawley rats were randomly 
assigned to four groups (n = 3 each): a control group, in which the rats did not receive BMP; a 
low-dose group where the rats received a dose of 10 mg/kg of BMP (i.p.); and two high-dose 
groups where rats were injected with a dose of 30 mg/kg (i.p.). The rats from the low-dose and 
one of the two high-dose groups were euthanized by CO2 asphyxiation, within 20 min. Those 
from the other high-dose group were euthanized by CO2 asphyxiation 90 min post-injection. 
Perimortem blood samples were obtained from the rat heart (cardiac puncture). The blood was 
collected in sodium fluoride vacutainer tubes obtained from BD (Mississauga, ON, Canada). 
5.2.2    Sample Pretreatment and Extraction 
The collected cardiac WB samples were pretreated and extracted following the MMSPE 
extraction method (see 2.4). These extracted samples were analyzed by the validated assay for 
selected ARDs using UPLC-qTOF-MS (see Chapter 4). 
5.2.3    Concentration Determination  
Two standard curves were constructed using six calibrators samples in duplicate for each 
analyte. Calibrators were prepared in a drug-free rat cardiac WB matrix (control group). Rat WB 
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calibrators (250 μL) were assayed at concentrations of 20, 40, 200, 500, 800, and 1,000 ng/mL 
using a combined working standard solution, with addition of 125 ng ISs to each calibrant. 
Quantification was performed based on the ratio of the integrated area under EIC of BMP to that 
of amphetamine-d11 using specific quantifier ions (see Table 30).  
5.2.4    Detection and Identification of Metabolites 
The identification process of the BMP metabolite was carried out by comparison with drug-
free samples. Molecular or fragmented ions uniquely found in LE mass spectral profiles of BMP-
dosed samples were considered potential metabolites and were used for subsequent analysis by 
examining their HE mass spectral profiles.   
5.3    Results 
 
The UPLC-qTOF-MS data for BMP in rat drug-free perimortem WB samples prepared by 
MMSPE are summarized in Table 30 and are shown in Figure 44. 
5.3.1    Concentration Determination  
BMP concentrations were fit with quadratic regression lines, and concentration dependence 
was assessed over a range of 20–1,000 ng/mL. The results showed a strong correlation (R2 > 
0.99). Table 34 shows the averaged calibration curve regression equation and correlation 
coefficient, and Figure 45 shows the averaged quadratic calibration curve. The BMP 
concentrations in the rat cardiac WB of the three groups (low, high, and high delayed groups) 
were determined using the averaged quadratic regression equation of the two constructed 
standard curves (see Figures 46 and 47). The determined concentrations of BMP are shown in 
Table 31. All determined concentrations (22–899 ng/mL) were within the validated working 
range of the assay (20–1,000 ng/mL). 
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5.3.2    Metabolite Detection and Identification  
A molecular or fragmented ion uniquely found in LE mass spectral profiles of BMP-dosed 
samples was considered the potential metabolite and was used for subsequent analysis by 
examining their HE mass spectral profiles. A fragmented ion was detected with a relatively high 
instrumental response in the high-dose group samples, whereas its intensity was low in the low-
dose and delayed high-dose samples. Figures 48 and 49 show the EIC and mass spectral profiles 
of the detectable metabolite, respectively. A comparative approach was used to compare EICs 
and mass spectra of the proposed metabolite with those of NOR (Figures 50, 51, and 52) and 
CAT (Figures 50, 53, and 54). Based on the metabolic pathway of AMP, a metabolic pathway of 
BMP was proposed as shown in Figure 55. The proposed metabolite was assumed to be 1-amino-
2-phenylpropano-2-ol. Figures 56, 57 and 58, 59 show the chemical structure of the proposed 
metabolite and its fragmentation patterns, respectively. 
 
Table 30: Analytical parameters of -methylphenethylamine and amphetamine-d11 
*Quantifier ion 
 
 
Table 31: Regression equation and correlation coefficient of a beta-methylphenethylamine 
concentration curve in rat perimortem whole blood 
Drug Ionization 
Mode 
Molecular Ion 
(m/z) 
Fragmented Ion (m/z) 
(± 0.01) 
Retention Time (min) 
(± 0.05) 
Amphetamine-d11 Positive 147.1938 98.1000*/130.1653 9.43 
β-methylphenethylamine 
 
Positive 136.1219 91.0553/119.0868* 10.28 
 
Analyte 
 
Linear Range 
(ng/mL) 
 
Regression Equation 
 
R2 
 
β-methylphenethylamine 
 
 
20–1,000 
 
𝑦 = −9 𝑥 10−8𝐶2 + 0.0005 𝐶 + 0.003 
 
0.9995 
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Figure 44; Total ion chromatogram of extracted rat postmortem whole blood; (A) drug-free 
control, and (B) spiked with 800 ng/mL of the combined working solution and 500 ng/mL of the 
internal standard solution; (1) ephedrine-d3, (2) amphetamine-d11 and (3) -
methylphenethylamine. 
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Figure 45: Averaged quadratic calibration curve of -methylphenethylamine. Error bars 
represent the standard error of the mean of the response ratio of duplicate samples at each 
concentration level 
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 Table 32: Concentrations of -methylphenethylamine in perimortem whole-blood (rat, n=9) samples 
 
Dose Calculated Concentration (ng/mL) 
Average 
(ng/mL) 
STDEV 
(ng/mL) 
Low Dose    
Rat 1 132 
104 25 Rat 2 96 
Rat 3 85 
High Dose 
   
Rat 1 868 
869 29 Rat 2 841 
Rat 3 899 
High Delayed Dose  
   
Rat 1 40 
31 9 Rat 2 22 
Rat 3 32 
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Figure 46: Extracted ion chromatograms (A–E) obtained using the molecular ion m/z 119 for        
-methylphenethylamine from extracts of perimortem whole-blood (rat) samples: (A) high 
delayed-dose, (B) high-dose, and (C) low-dose; (D) calibrant at a concentration of 1,000 ng/mL; 
(E) drug-free control 
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Figure 47: Mass spectral profile (A–D) of -methylphenethylamine in extracts of perimortem 
whole-blood samples: (A) high delayed -dose, (B) high-dose, and (C) low-dose; (D) calibrant 
at a concentration of 1,000 ng/mL 
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Figure 48: Extracted ion chromatograms (A–D) obtained using the fragmented ion m/z 134 for 
-methylphenethylamine in extracts of perimortem whole-blood samples: (A) high delayed-dose, 
(B) high-dose, and (C) low-dose; (D) drug-free control. 
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Figure 49: Mass spectra of the proposed metabolite of -methylphenethylamine obtained at low 
energy (A) and high energy (B). 
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Figure 50: Extracted ion chromatograms obtained using the fragmented ion m/z 134 for (A) the 
metabolite of -methylphenethylamine in extracts of the high-dose rat perimortem whole-blood 
samples and (B) norephedrine and cathine at a concentration of 20 ng/mL in the calibrant. 
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Figure 51: Mass spectra obtained at low energy for (A) the proposed metabolite of                               
-methylphenethylamine and (B) norephedrine at a concentration of 20 ng/mL. 
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Figure 52: Mass spectra obtained at high energy for (A) the proposed metabolite of  
-methylphenethylamine and (B) norephedrine at a concentration of 20 ng/mL. 
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Figure 53: Mass spectra obtained at low energy for (A) the proposed metabolite of                               
-methylphenethylamine and (B) cathine at a concentration of 20 ng/mL. 
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Figure 54: Mass spectra obtained at high energy for (A) the proposed metabolite of                  
-methylphenethylamine and (B) cathine at a concentration of 20 ng/mL. 
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Figure 55: Proposed metabolic pathway of -methylphenethylamine. 
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Figure 56: Proposed chemical structures of the putative metabolites of -methylphenethylamine. 
 
 
Figure 57: Proposed fragmentation pattern of the metabolite of -methylphenethylamine. 
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Figure 58: Second proposed fragmentation pattern of the metabolite of -methylphenethylamine. 
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Figure 59: Proposed fragmentation pattern of the metabolite of -methylphenethylamine 
presented on the mass spectral profile of -methylphenethylamine, obtained at high energy.  
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5.4    Discussion 
The validated analytical assay for the identification and quantification of selected ARDs in 
WB using MMSPE and UPLC-qTOF-MS was applied to the determination of BMP 
concentrations and detecting its metabolite in rat cardiac WB in this study. Post-injection rat WB 
samples were pretreated and extracted following the MMSPE pretreatment and extraction 
method (see 2.4). The extracted samples were analyzed using the validated analytical procedure 
described in Chapter 4.  
The identification of BMP in rat WB was based on agreement between the putative compound 
and BMP (calibrator) in relative intensity at m/z 136, 119, and 91and retention time. The EIC 
(m/z = 119) and mass spectrum of a calibrant sample (positive control) corresponded to those 
from a sample derived from a drug-positive rat in terms of the relative instensity of the fragment 
ions formed and retention times. The S/N ratios were above the lower acceptable limits of 3:1 for 
m/z 136 and 91(qualifiers ions) and 10:1 for m/z 119 (quantifier ion) in all drug-postive rat WB 
samples. BMP quantification was based on the averaged standard curve using drug-free cardiac 
rat WB (control group), fit with a quadratic regression equation (R2 = 0.9995); Table 30, Figure 
45. The measured concentrations of BMP are shown in Table 35. The highest determined 
concentration of BMP was 899 ng/mL in a sample obtained from the high-dose group, whereas 
the lowest determined concentration was 22 ng/mL in a sample collected from the high delayed-
dose group. Both the highest and lowest determined concentrations were within the validated 
working range of the assay (20-1,000 ng/mL). Interestingly, the high delayed-dose samples 
(collected 90 min post-injection) showed a sharp decline in the concentration levels of BMP (31 
ng/mL ± 9 ng/mL) compared to the high-dose samples (collected within 20 min of injection), 
which showed very high concentration levels of BMP (869 ng/mL ± 29 ng/mL). This finding 
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proved that BMP has a short half-life of elimination from the rat blood. Further experiments are 
required to precisely estimate the half-life of BMP.  
The main purpose of this study was to apply the validated method to authentic samples from 
subjects exposed to BMP and to identify one or more BMP metabolites. A theoretical metabolic 
pathway of BMP is proposed in Figure 55. This metabolic pathway was proposed based on the 
published metabolic pathway of AMP [173]. According to this theoretical metabolic pathway, 4-
hydroxy-β-methylphenethylamine (4-HYDROXY), 1-amino-2-phenylpropan-2-ol (1-AMINO), 
and 4-(1-amino-2-hydroxypropan-2-yl) phenol (4-PHENOL) were proposed to be the 
metabolites of BMP. These proposed metabolites may be expected to be detectable by the 
analytical method proposed here, whereas 2-phenylpropanol, benzoic acid, and hippuric acid 
may not be detectable in positive ionization mode. A method for detection of putative 
metabolites by negative ionization mode was not developed in this work. 
The metabolite identification process was carried out through manual and automated searches. 
The manual search process was performed using Masslynx® software, through search for 
molecular ions of common metabolite products (e.g., hydroxylation products). As was observed 
through analysis of the EICs corresponding to [M+H] (i.e., m/z = 152; hydroxylated metabolite 
of BMP) or [M+H+16] (e.g., m/z = 168; doubly hydroxylated metabolite of BMP), no detectable 
compounds were observed. Considering the fragmentation phenomena of the molecular ions of 
analytes included in validation within the qTOF-MS used, it is reasonable to anticipate similar 
patterns with any observed BMP metabolites.  
The ion focusing system used in the XEVO-G2XS qTOF-MS is known as the StepWave® 
(see Figure 4) system, which plays a significant role in transferring ions from the ion source to 
the first mass filter (quadrupole). The StepWave® uses a relatively high electric field to guide 
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ions toward the first mass filter. Such an electric field may lead to “in-source” fragmentation of 
certain analytes prior to reaching the mass selector, especially at a low concentration level, 
leading to low sensitivity of detection of the molecular ion of an analyte. This phenomenon of in-
source fragmentation could explain the underlying reason for the inability to detect the molecular 
ions of the theoretically proposed metabolites. Interestingly, a compound producing the ion with 
m/z 134 was detectable in all extracts from drug-positive rats at HE and LE but not in those from 
the drug-free controls. Figures 48 and 49 show EICs (m/z = 134) and mass spectral profiles from 
extracts of drug-positive and drug-negative rats. The presence of a compound forming this ion in 
extracts from the drug-positive animals was demonstrated using the automated Metabolite 
Identification feature of the UNIFI® software. Unfortunately, UNIFI® was not able to 
conclusively determine the identity of the proposed metabolite, even though the software was 
able to detect the compound. Furthermore, a search through the scientific libraries of the 
UNIFI® software yielded more than 100 candidate compounds. Most of these candidate 
compounds were excluded based on their chemical structures and compositions (chemical 
formula and nominal mass). Two candidates underwent comparison with the proposed 
metabolite at the level of mass spectral profiles. These candidate compounds were 4-
hydroxyamphetamine and NOR. Since NOR was included in the validated method, its EIC and 
mass spectra at HE and LE were compared with those of the detectable metabolite, as shown in 
Figures 51, 52, and 53, respectively. There was agreement between the spectra of NOR and the 
proposed metabolite in the HE and LE mass spectra (Figure 52). However, the ion with m/z 152 
was not detectable in the mass spectrum of the proposed metabolite, probably due to in-source 
fragmentation, as suggested earlier. Surprisingly, the HE mass spectra of CAT and the proposed 
metabolite were in good agreement, as shown in Figure 54. These findings support the idea that 
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the proposed metabolite might be a positional isomer of phenylpropanolamine (NOR and CAT). 
Experimentally, this proposition was strengthened by comparison of the retention times of the 
proposed metabolite and NOR, which were 5.43 and 5.71 min, respectively, as shown in Figure 
50. This degree of resolution is consistent with that of the positional isomers included in the 
validated method (i.e. AMP and BMP). Accordingly, the metabolite of BMP was proposed to be 
1-AMINO (see Figure 56) which is the corresponding positional isomer of NOR in the proposed 
metabolic pathway of BMP (see Figure 55). Two fragmentation patterns were proposed for 1-
AMINO, as shown in Figures 57, 58, and 59. However, 4-HYDROXY could not be excluded as 
a candidate metabolite of BMP. Since a reference standard for 4-HYDROXY was not available 
for inclusion in this study, further investigation could not be carried out. Thus, further 
experiments are required to confirm the identity of the detected metabolite of BMP as 1-AMINO 
or 4-HYDROXY, or to exclude both candidates. This confirmatory study can be carried out by 
analyzing neat standards, and spiked WBs of 1-AMINO and 4-HYDROXY and comparing their 
mass spectra (HE and LE) with those of the metabolite of BMP detected in this study.  
5.5    Conclusion 
The validated analytical method for the identification and quantification of selected ARDs in 
WB using MMSPE and UPLC-qTOF-MS was verified by determining BMP concentrations and 
detecting its metabolite in rat cardiac WB in this study. Additionally, the study demonstrated the 
utility of UPLC-qTOF-MS for metabolite identification owing to its MSE scanning mode feature.  
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Chapter 6 
 
6.0     Conclusion  
6.1     General Conclusions 
A highly sensitive analytical method developed for selected ARDs was proven to be reliable 
for the detection and identification of a trace amount of EPH leaching from MIP-SPE. Although 
MIPs provide remarkable extraction selectivity by most analytical standards, the template 
compound leaching observed in this work measurably interfered with the analysis of one of the 
target analytes as a result of the high sensitivity and selectivity of the instrument and method 
used. Therefore, vendors should be wary of the potential for such interferences given that 
increasing sensitivity and mas resolution of LC-MS technology, and should be appropriately 
disclosed. Second, this study presents a validated method for the identification and quantification 
of selected ARDs by UPLC-qTOF-MS in WB after extraction by MMSPE. The method was 
validated according to the standard practices of SWGTOX, and. therefore, it can be utilized in 
forensic toxicology. Finally, the validated analytical assay was applied to measurement of BMP 
in WB of rats exposed to the drug, as well as to detection and potential identification of a putative 
BMP metabolite in rat cardiac WB. 
6.2     Future Work  
WB is one of the most complicated biological matrices available in forensic toxicology. 
Additionally, the chemical properties of ARDs add more complexity to the analytical approach 
for the detection of these drugs in WB. Therefore, further research is required to assist with and 
evaluate some of the challenges (e.g. the effects of non-silanized glass during sample preparation 
on detection of ARDs) faced during development and validation stages of this analytical method. 
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The research presented here used aged WB in developing a method for the identification and 
quantification of selected ARDs. This study was performed on aged animal WB matrices 
because of our limited access to aged human WB. This type of study should be expanded to 
include aged human WB.  
Metabolite identification is another complex issue, requiring advanced techniques and 
analytical strategies, especially when the detectable metabolite has never been reported in the 
literature, as was the case in the analysis of WB of BMP-exposed animals. The proposed 
metabolite of BMP needs further research to confirm its chemical identity and structure.    
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Appendix B 
 
 
 
Figure 1: Structure proposals of the molecular ion and some of the fragment ions in the product 
ion mass spectra of amphetamine-d11 
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Figure 2: M𝑆𝐸 (HE) spectra of amphetamine-d11 
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Figure 3: Structure proposals of the molecular ion and some of the fragment ions in the product 
ion mass spectra of ephedrine-d3 
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Figure 4: M𝑆𝐸 (HE) spectra of ephedrine-d3 
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Figure 5: Structure proposals of the molecular ion and some of the fragment ions in the product 
ion mass spectra of phenylpropanolamine (norephedrine and cathine) 
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Figure 6: M𝑆𝐸 (HE) spectra of norephedrin 
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Figure 7: M𝑆𝐸 (HE) spectra of cathine 
Cathine 2: TOF MS ES+ 
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Figure 8: Structure proposals of the molecular ion and some of the fragment ions in the product 
ion mass spectra of methyl phenylpropanolamine (ephedrine and pseudoephedrine) 
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Figure 9: M𝑆𝐸 (HE) spectra of ephedrine 
Ephedrine 2: TOF MS ES+ 
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Figure 10: M𝑆𝐸 (HE) spectra of pseudoephedrine 
Pseudoephedrine 2: TOF MS ES+ 
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Figure 11: Structure proposals of the molecular ion and some of the fragment ions in the product 
ion mass spectra of amphetamine 
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Figure 12: M𝑆𝐸 (HE) spectra of amphetamine 
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Figure 13: Structure proposals of the molecular ion and some of the fragment ions in the product 
ion mass spectra of etamethylphenethylamie 
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Figure 14: M𝑆𝐸 (HE) spectra of -methylphenethylamine 
Beta-methylphenethylamine 1: TOF MS ES+ 
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